{"id":"cemiplimab","rwe":[{"pmid":"41899521","year":"2026","title":"Association Between Patient-Reported Outcomes and Overall Survival in Patients with Advanced NSCLC Treated with First-Line Cemiplimab-Based Therapy.","finding":"","journal":"Cancers","studyType":"Clinical Study"},{"pmid":"41869512","year":"2026","title":"First-Line Cemiplimab for Locally Advanced NSCLC: Updated Subgroup Analyses From the EMPOWER-Lung 1 and EMPOWER-Lung 3 Trials.","finding":"","journal":"JTO clinical and research reports","studyType":"Clinical Study"},{"pmid":"41868132","year":"2026","title":"Effectiveness and safety of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.","finding":"","journal":"Frontiers in pharmacology","studyType":"Clinical Study"},{"pmid":"41861397","year":"2026","title":"Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non-small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparison.","finding":"","journal":"Journal of medical economics","studyType":"Clinical Study"},{"pmid":"41855018","year":"2026","title":"ASO Visual Abstract: The Role of Cemiplimab in Treating Locally Advanced Cutaneous SCC-A UK Single-Centre Experience and the Implications for Surgical Management.","finding":"","journal":"Annals of surgical oncology","studyType":"Clinical Study"}],"_fda":{"id":"1e241c47-2ccb-434e-95f5-d45aa9e1ecf3","set_id":"4347ae1f-d397-4f18-8b70-03897e1c054a","openfda":{"unii":["6QVL057INT"],"route":["INTRAVENOUS"],"rxcui":["2058830","2058835"],"spl_id":["1e241c47-2ccb-434e-95f5-d45aa9e1ecf3"],"brand_name":["LIBTAYO"],"spl_set_id":["4347ae1f-d397-4f18-8b70-03897e1c054a"],"package_ndc":["61755-008-01"],"product_ndc":["61755-008"],"generic_name":["CEMIPLIMAB-RWLC"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["CEMIPLIMAB"],"manufacturer_name":["Regeneron Pharmaceuticals, Inc."],"application_number":["BLA761097"],"is_original_packager":[true]},"version":"22","pregnancy":["8.1 Pregnancy Risk Summary Based on its mechanism of action, LIBTAYO can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no available data on the use of LIBTAYO in pregnant women. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death (see Data ) . Human IgG4 immunoglobulins (IgG4) are known to cross the placenta; therefore, LIBTAYO has the potential to be transmitted from the mother to the developing fetus. Advise women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Animal reproduction studies have not been conducted with LIBTAYO to evaluate its effect on reproduction and fetal development. A central function of the PD-1/PD-L1 pathway is to preserve pregnancy by maintaining maternal immune tolerance to the fetus. In murine models of pregnancy, blockade of PD-L1 signaling has been shown to disrupt tolerance to the fetus and to result in an increase in fetal loss; therefore, potential risks of administering LIBTAYO during pregnancy include increased rates of abortion or stillbirth. As reported in the literature, there were no malformations related to the blockade of PD-1/PD-L1 signaling in the offspring of these animals; however, immune-mediated disorders occurred in PD-1 and PD-L1 knockout mice. Based on its mechanism of action, fetal exposure to cemiplimab-rwlc may increase the risk of developing immune-mediated disorders or altering the normal immune response."],"description":["11 DESCRIPTION Cemiplimab-rwlc is a human programmed death receptor-1 (PD-1) blocking antibody. Cemiplimab-rwlc is a recombinant human IgG4 monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2. Cemiplimab-rwlc is produced by recombinant DNA technology in Chinese hamster ovary (CHO) cell suspension culture. Cemiplimab-rwlc has an approximate molecular weight of 146 kDa. LIBTAYO (cemiplimab-rwlc) injection for intravenous use is a sterile, preservative-free, clear to slightly opalescent, colorless to pale yellow solution with a pH of 6. The solution may contain trace amounts of translucent to white particles. Each vial contains 350 mg of cemiplimab-rwlc. Each mL contains cemiplimab-rwlc 50 mg, L-histidine (0.74 mg), L-histidine monohydrochloride monohydrate (1.1 mg), sucrose (50 mg), L-proline (15 mg), polysorbate 80 (2 mg), and Water for Injection, USP."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING LIBTAYO (cemiplimab-rwlc) injection is a clear to slightly opalescent, colorless to pale yellow solution that may contain trace amounts of translucent to white particles. It is supplied in a carton containing 1 single-dose vial of: 350 mg/7 mL (50 mg/mL) (NDC 61755-008-01) Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton. Protect from light. Do not freeze or shake."],"spl_medguide":["This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: October 2025 MEDICATION GUIDE LIBTAYO ® (Lib-TIE-oh) (cemiplimab-rwlc) injection What is the most important information I should know about LIBTAYO? LIBTAYO is a medicine that may treat certain types of cancers by working with your immune system. LIBTAYO can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended. Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including: Lung problems. cough shortness of breath chest pain Intestinal problems. diarrhea (loose stools) or more frequent bowel movements than usual stools that are black, tarry, sticky, or have blood or mucus severe stomach-area (abdomen) pain or tenderness Liver problems. yellowing of your skin or the whites of your eyes severe nausea or vomiting pain on the right side of your stomach-area (abdomen) dark urine (tea colored) bleeding or bruising more easily than normal Hormone gland problems. headache that will not go away or unusual headaches eye sensitivity to light eye problems rapid heartbeat increased sweating extreme tiredness weight gain or weight loss feeling more hungry or thirsty than usual urinating more often than usual hair loss feeling cold constipation your voice gets deeper dizziness or fainting changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness Kidney problems. decrease in your amount of urine blood in your urine swelling of your ankles loss of appetite Skin problems. rash itching skin blistering or peeling painful sores or ulcers in mouth or nose, throat, or genital area fever or flu-like symptoms swollen lymph nodes Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with LIBTAYO. Call or see your healthcare provider right away for any new or worsening signs or symptoms which may include: chest pain, irregular heartbeat, shortness of breath or swelling of ankles confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight persistent or severe muscle pain or weakness, muscle cramps low red blood cells, bruising Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: nausea vomiting chills or shaking itching or rash flushing shortness of breath or wheezing dizziness feel like passing out fever back or neck pain facial swelling Rejection of a transplanted organ or tissue. Your healthcare provider should tell you what signs and symptoms you should report and monitor you, depending on the type of organ or tissue transplant that you have had. Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with LIBTAYO. Your healthcare provider will monitor you for these complications. Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with LIBTAYO. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with LIBTAYO if you have severe side effects. What is LIBTAYO? LIBTAYO is a prescription medicine used to treat adults with: a type of skin cancer called cutaneous squamous cell carcinoma (CSCC). LIBTAYO may be used: to treat CSCC that has spread or cannot be cured by surgery or radiation, or to help prevent CSCC from coming back if your CSCC is at high risk of coming back after it has been removed by surgery and radiation. a type of skin cancer called basal cell carcinoma (BCC). LIBTAYO may be used when your BCC cannot be removed by surgery (locally advanced BCC) or when it has spread (metastatic BCC), and you have previously received treatment with a hedgehog pathway inhibitor (HHI), or you cannot receive treatment with a HHI. a type of lung cancer called non-small cell lung cancer (NSCLC). LIBTAYO may be used in combination with chemotherapy that contains a platinum medicine as your first treatment when your lung cancer: has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor does not have an abnormal \"EGFR\", \"ALK\" or \"ROS1\" gene. LIBTAYO may be used alone as your first treatment when your lung cancer: has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor tests positive for high \"PD-L1\" and your tumor does not have an abnormal \"EGFR\", \"ALK\" or \"ROS1\" gene It is not known if LIBTAYO is safe and effective in children. Before you receive LIBTAYO, tell your healthcare provider about all your medical conditions, including if you: have immune system problems such as Crohn's disease, ulcerative colitis, or lupus have received an organ or tissue transplant, including corneal transplant have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic) have received radiation treatment to your chest area have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome are pregnant or plan to become pregnant. LIBTAYO can harm your unborn baby. Females who are able to become pregnant: Your healthcare provider will give you a pregnancy test before you start treatment with LIBTAYO. You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of LIBTAYO. Talk to your healthcare provider about birth control methods that you can use during this time. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with LIBTAYO. are breastfeeding or plan to breastfeed. It is not known if LIBTAYO passes into your breast milk. Do not breastfeed during treatment and for at least 4 months after the last dose of LIBTAYO. Tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. How will I receive LIBTAYO? Your healthcare provider will give you LIBTAYO into your vein through an intravenous (IV) line over 30 minutes. LIBTAYO is usually given every 3 weeks or every 6 weeks depending on the dose of LIBTAYO you are receiving. Your healthcare provider will decide how many treatments you will need. Your healthcare provider will do blood tests to check you for side effects. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. What are the possible side effects of LIBTAYO? LIBTAYO can cause serious side effects. See \" What is the most important information I should know about LIBTAYO? \" The most common side effects of LIBTAYO when used alone to treat CSCC that has spread or cannot be cured by surgery or radiation, BCC or NSCLC include: tiredness muscle or bone pain rash diarrhea low levels of red blood cells (anemia) The most common side effects of LIBTAYO when used alone to help prevent CSCC from coming back include: rash itching The most common side effects of LIBTAYO when used in combination with platinum-containing chemotherapy to treat NSCLC include: hair loss muscle or bone pain nausea tiredness numbness, pain, tingling or burning in your hands or feet decreased appetite These are not all the possible side effects of LIBTAYO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. General information about the safe and effective use of LIBTAYO. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about LIBTAYO that is written for health professionals. What are the ingredients of LIBTAYO? Active ingredient: cemiplimab-rwlc Inactive ingredients: L-histidine, L-histidine monohydrochloride monohydrate, sucrose, L-proline, Polysorbate 80, and Water for Injection. Manufactured by: Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 U.S. License No. 1760 Marketed by: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591) For more information, call 1-877-542-8296 ©2025 Regeneron Pharmaceuticals, Inc. All rights reserved."],"geriatric_use":["8.5 Geriatric Use LIBTAYO as a Single Agent Of the 1281 patients with advanced cancers who received LIBTAYO as a single agent in clinical studies, 26% were 65 years up to 75 years and 22% were 75 years or older. No overall differences in safety or effectiveness were observed between these patients and younger patients. Of the 358 patients with mCSCC or laCSCC who received LIBTAYO as a single agent in Study 1540, 30% were 65 years up to 75 years and 48% were 75 years or older. No overall differences in safety or effectiveness were observed between these patients and younger patients. Of the 205 adult patients with CSCC at high-risk of recurrence who received LIBTAYO as a single agent in the C-POST study, 39% were 65 years up to 75 years and 35% were 75 years or older. No overall differences in safety or effectiveness were observed between these patients and younger patients. Of the 138 patients with BCC who received LIBTAYO as a single agent in Study 1620, 27% were 65 years up to 75 years, and 31% were 75 years or older. No overall differences in safety or effectiveness were observed between these patients and younger patients. LIBTAYO in Combination with Platinum-based Chemotherapy Of the 312 patients with NSCLC who received LIBTAYO in combination with platinum-based chemotherapy in Study 16113, 35% were 65 years up to 75 years and 6% were 75 years or older. No overall differences in safety or effectiveness were observed between these patients and younger patients."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of LIBTAYO have not been established in pediatric patients. The safety and efficacy of LIBTAYO as a single agent (Part 1, N=25) or in combination with radiation therapy (Part 2, N=22) were evaluated but not established in a two-part, open-label, multi-center trial (Study 1690, NCT03690869) in pediatric patients (birth to < 17 years) with relapsed or refractory solid tumors (Part 1) or relapsed or refractory CNS tumors (Parts 1 and 2) or newly diagnosed CNS tumors (Part 2). No new safety signals were observed in these pediatric patients. Cemiplimab exposure in 46 pediatric patients aged 1 to < 17 years was within the range of values previously observed in adults given a similar dose based on body weight."],"effective_time":"20251029","clinical_studies":["14 CLINICAL STUDIES 14.1 Cutaneous Squamous Cell Carcinoma (CSCC) Advanced CSCC The efficacy of LIBTAYO in patients with metastatic (nodal or distant) cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who were not candidates for curative surgery or curative radiation was evaluated in two open-label, multi-center, non-randomized, multicohort studies: Study 1423 (NCT02383212) and Study 1540 (NCT02760498). Both studies excluded patients with autoimmune disease that required systemic therapy with immunosuppressant agents within 5 years; history of solid organ transplant; prior treatment with anti–PD-1/PD-L1 blocking antibodies or other immune checkpoint inhibitor therapy; infection with HIV, hepatitis B or hepatitis C; or ECOG PS ≥2. Patients received LIBTAYO 3 mg/kg intravenously every 2 weeks for up to 48 weeks in Study 1423 or up to 96 weeks (Groups 1 and 2), or 350 mg every 3 weeks for up to 54 weeks (Group 3) in Study 1540. Treatment continued until progression of disease, unacceptable toxicity, or completion of planned treatment. Tumor response assessments were performed every 8 or 9 weeks. The major efficacy outcome measures were confirmed objective response rate (ORR), defined as complete response (CR) plus partial response (PR) as assessed by independent central review (ICR), and ICR-assessed duration of response (DOR). For patients with mCSCC without externally visible target lesions, ORR was determined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1). For patients with externally visible target lesions (laCSCC and mCSCC), ORR was determined by a composite endpoint that integrated ICR assessments of radiologic data (RECIST 1.1) and digital medical photography (WHO criteria). Study 1540 In the efficacy analysis of 193 patients with advanced CSCC enrolled in Study 1540 who received LIBTAYO at either 3 mg/kg every 2 weeks or 350 mg every three weeks, 115 had mCSCC and 78 had laCSCC. The median age was 72 years (38 to 96 years); 83% were male; 97% were White, 2% were Asian, 1% were Black or African American, and 1% were race unknown; 45% had ECOG PS 0 and 55% had ECOG PS 1; 34% received at least one prior anti-cancer systemic therapy; 81% received prior cancer-related surgery; and 68% received prior radiotherapy. Among patients with mCSCC, 77% had distant metastases and 23% had only nodal metastases. For the responding patients presented in Table 13 below, the median time to response was 2.1 months (range: 1.7 to 22.8 months). Efficacy results based on the final analysis of Study 1540 are presented in Table 13. Table 13: Efficacy Results for Study 1540 in Advanced CSCC Efficacy Endpoints Median duration of follow up: mCSCC 3 mg/kg every 2 weeks: 18.5 months; laCSCC 3 mg/kg every 2 weeks: 15.5 months; mCSCC 350 mg every 3 weeks: 17.3 months; combined CSCC: 15.7 months Metastatic CSCC LIBTAYO 3 mg/kg every 2 weeks (Group 1) Locally Advanced CSCC LIBTAYO 3 mg/kg every 2 weeks (Group 2) Metastatic CSCC LIBTAYO 350 mg every 3 weeks (Group 3) Combined CSCC N = 59 N = 78 N = 56 N = 193 CI: confidence interval; NR: not reached Confirmed Objective Response Rate (ORR) (%) ORR (95% CI) 51 (37, 64) 45 (34, 57) 46 (33, 60) 47 (40, 54) Complete response rate Only includes patients with complete healing of prior cutaneous involvement; laCSCC patients in Study 1540 required biopsy to confirm CR 20 13 20 17 Partial response rate 31 32 27 30 Duration of Response (DOR) Number of Responders N = 30 N = 35 N = 26 N = 91 Median DOR in months Based on Kaplan-Meier estimate (Range) NR (2.8 – 38.9) 42 (1.9 – 54.6) 41 (4.2 – 46.3) 41 (1.9 – 54.6) Patients with observed DOR ≥6 months, n (%) The numerator includes the number of patients whose observed DOR reached at least the specified times of 6 or 12 months. Patients who did not have the opportunity to reach the specified timepoint were included in the denominator only 28 (93%) 31 (89%) 25 (96%) 84 (92%) Patients with observed DOR ≥12 months, n (%) 23 (77%) 24 (69%) 23 (88%) 70 (77%) Study 1423 Among 26 CSCC patients in Study 1423, 16 had mCSCC and 10 had laCSCC. The median age was 73 years (52 to 88 years); 81% of patients were male; 92% of patients were White; the ECOG PS was 0 (38%) and 1 (62%); 58% of patients had received at least 1 prior anti-cancer systemic therapy; 92% of patients had received prior cancer-related surgery and 81% had received prior radiotherapy. One patient in the mCSCC group was dosed at 1 mg/kg. The rest received 3 mg/kg every 2 weeks. With a median duration of follow-up of 13.3 months, the confirmed ORR was 50% (95% CI: 30, 70); all responses were PRs. The median time to response was 1.9 months (range: 1.7 to 7.3 months) and 85% of responders had a DOR ≥6 months. Adjuvant treatment of CSCC at high risk of recurrence after surgery and radiation. The efficacy of LIBTAYO was evaluated in the C-POST study (NCT03969004), a randomized, double-blind, multicenter, placebo-controlled trial in 415 patients with CSCC at high risk of recurrence after surgery and radiation. Patients were required to complete adjuvant radiation therapy within 2 to 10 weeks of randomization. High risk of recurrence was defined as at least one of the following features: Nodal Features: Extracapsular extension (ECE) with ≥1 node ≥20 mm, or ≥3 involved lymph nodes regardless of ECE Non-Nodal Features: In-transit metastases (skin or subcutaneous metastases > 2 cm from the primary lesion but not beyond the regional nodal basin), Invasion of the skeleton or base of the skull (T4 Lesion), Perineural Invasion, or Locally recurrent tumor with ≥1 additional adverse feature listed below: Multiple ipsilateral nodes ≥T3 (≥4 cm diameter or bone erosion or invasion >6 mm) Poorly differentiated histology and recurrent lesion ≥20 mm diameter The study excluded patients with autoimmune disease that required systemic therapy with immunosuppressant agents within 5 years; history of solid organ transplant; prior allogeneic or autologous stem cell transplantation; uncontrolled HIV, hepatitis B or hepatitis C infection, or ECOG PS ≥2. Patients were randomized 1:1 to receive LIBTAYO (N=209) or placebo (n=206). In the LIBTAYO arm, 171 patients received 350 mg LIBTAYO intravenously every 3 weeks for 12 weeks, followed by 700 mg LIBTAYO intravenously every 6 weeks for an additional 36 weeks, and 38 patients received 350 mg LIBTAYO intravenously every 3 weeks for up to 48 weeks. Treatment continued until disease recurrence, unacceptable toxicity, or up to 48 weeks. The major efficacy outcome measure was disease-free survival (DFS) defined as time from randomization to the first documented disease recurrence by investigator assessment or death due to any cause. Overall survival was an additional outcome measure. The median age was 71 years (range: 33 to 95); 84% were male; 91% were White, 3.1% were Asian, 5.4% were unknown or not reported, 0.5% were other; 9.4% were Hispanic or Latino, 83.4% were not Hispanic or Latino, 7% were unknown or not reported; 64% had ECOG PS of 0 and 36% had ECOG PS of 1. The location of tumor was head and neck (HN) in 83% of patients and non-HN in 17% of patients. The high-risk of recurrence feature was nodal in 58% of patients and non-nodal in 42% of patients. A statistically significant improvement in DFS was demonstrated in patients randomized to LIBTAYO compared with placebo. Improvement in DFS was similar in both dosage regimens. Efficacy results in C-POST study are summarized in Table 14 and Figure 1. Table 14: Efficacy Results for the C-POST Study in Patients with CSCC at High Risk of Recurrence in the Adjuvant Setting Efficacy Endpoints LIBTAYO Placebo N = 209 N = 206 CI: confidence interval; NE: not evaluable; NR: not reached Disease-Free Survival (DFS) Number of events, n (%) 24 (12%) 65 (32%) Disease recurrences, n (%) Distant recurrence, n (%) Locoregional recurrence, n (%) 18 (9%) 10 (4.8%) 8 (3.8%) 61 (30%) 26 (13%) 35 (17%) Deaths, n (%) 6 (2.9%) 4 (1.9%) Median (95% CI) in months Based on Kaplan-Meier method NR (NE, NE) 49.4 (48.5, NE) Hazard ratio (95% CI) Based on stratified proportional hazards model 0.32 (0.20, 0.51) p-value Based on a two-sided stratified log-rank test <0.0001 Figure 1: Kaplan-Meier Curve of DFS in the C-POST study Figure 1 14.2 Basal Cell Carcinoma (BCC) The efficacy of LIBTAYO in 138 patients with advanced basal cell carcinoma (BCC) [unresectable locally advanced (laBCC) or metastatic (nodal or distant) (mBCC)] who had progressed on hedgehog pathway inhibitor (HHI) therapy, had not had an objective response after 9 months on HHI therapy, or were intolerant of prior HHI therapy was evaluated in Study 1620 (NCT03132636), an open-label, multi-center, non-randomized study. The study excluded patients with autoimmune disease that required systemic therapy with immunosuppressant agents within 5 years; history of solid organ transplant; prior treatment with anti–PD-1/PD-L1 therapy or other immune checkpoint inhibitor therapy; infection with HIV, hepatitis B or hepatitis C; or ECOG performance score (PS) ≥2. Patients received LIBTAYO 350 mg every 3 weeks for up to 93 weeks until disease progression, unacceptable toxicity, or completion of planned treatment. Tumor assessments were performed every 9 weeks for the first 45 weeks of treatment and every 12 weeks thereafter. The major efficacy outcome measures were confirmed objective response rate (ORR) and duration of response (DOR) as assessed by independent central review (ICR). For patients with mBCC without externally visible target lesions, ORR was determined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1). For patients with externally visible target lesions (laBCC and mBCC), ORR was determined by a composite endpoint that integrated ICR assessments of radiologic data (RECIST 1.1) and digital medical photography (WHO criteria). A total of 138 patients with advanced BCC were included in the efficacy analysis of Study 1620. Of these, 39% had mBCC and 61% had laBCC. In patients with laBCC, the median age was 70 years (42 to 89 years); 67% were male; 68% were White and 32% were race not reported/unknown; 61% had ECOG PS 0 and 39% had ECOG PS 1; 83% had received at least 1 prior cancer-related surgery; and 50% had received prior radiotherapy. In patients with mBCC, the median age was 63.5 years (38 to 90 years); 70% were male; 87% were White and 13% were race not reported/unknown; 67% had ECOG PS 0 and 33% had ECOG PS 1; 85% had received at least 1 prior cancer-related surgery; and 59% had received prior radiotherapy. Among patients with mBCC, 35% had distant metastases only, 9% had nodal disease only, and 54% had both distant and nodal disease. Efficacy results are presented in Table 15. For the responding patients, the median time to response was 3.1 months (range 2 to 10.5 months) for the mBCC group and 4.3 months (range 2.1 to 21.4 months) for the laBCC group. Table 15: Efficacy Results for Study 1620 in BCC Efficacy Endpoints Median duration of follow up: mBCC 8.4 months; laBCC 15.9 months Metastatic BCC Locally Advanced BCC N = 54 N = 84 CI: confidence interval; NR: not reached; +: denotes ongoing at last assessment Confirmed Objective Response Rate (ORR) (%) ORR (95% CI) 22 (12, 36) 32 (22, 43) Complete response rate 1.9 7 Partial response rate 20 25 Duration of Response Number of Responders N = 12 N = 27 Median DOR in months Based on Kaplan-Meier estimate (Range) 16.7 (9.0 – 25.8+) NR (2.1 – 36.8+) Patients with observed DOR ≥6 months, n (%) 12 (100%) 23 (85%) 14.3 Non-Small Cell Lung Cancer (NSCLC) First-line treatment of NSCLC with LIBTAYO in combination with platinum-based chemotherapy The efficacy of LIBTAYO in combination with platinum-based chemotherapy was evaluated in Study 16113 (NCT03409614), a randomized, multi-center, double-blind, active-controlled trial in 466 patients with locally advanced NSCLC who were not candidates for surgical resection or definitive chemoradiation or with metastatic NSCLC who had not previously received systemic treatment for metastatic NSCLC. Patients were eligible regardless of tumor PD-L1 expression status. Patients with EGFR, ALK or ROS1 genomic tumor aberrations; a medical condition that required systemic immunosuppression; or ongoing or recent autoimmune disease that required systemic therapy were ineligible. Patients with a history of brain metastases were eligible if they had been adequately treated and had neurologically returned to baseline for at least 2 weeks prior to randomization. Randomization was stratified by histology (non-squamous vs squamous) and PD-L1 expression (<1% versus 1% to 49% versus ≥50%) according to the VENTANA PD-L1 (SP263) assay. Patients were randomized (2:1) to receive either: LIBTAYO 350 mg intravenously (IV) every 3 weeks for 108 weeks plus platinum-based chemotherapy every 3 weeks for 4 cycles, or placebo IV every 3 weeks for 108 weeks plus platinum-based chemotherapy every 3 weeks for 4 cycles. Platinum-based chemotherapy in either arm consisted of carboplatin AUC of 5 or 6 and paclitaxel 200 mg/m 2 ; cisplatin 75 mg/m 2 and paclitaxel 200 mg/m 2 ; carboplatin AUC of 5 or 6 and pemetrexed 500 mg/m 2 ; or cisplatin 75 mg/m 2 and pemetrexed 500 mg/m 2 . Maintenance pemetrexed was mandatory for patients with non-squamous NSCLC who received a pemetrexed-containing chemotherapy regimen in the first 4 treatment cycles. Study treatment continued until RECIST 1.1-defined progressive disease, unacceptable toxicity, or 108 weeks. Assessment of tumor status was performed every 9 weeks during year 1 and every 12 weeks after year 1. The major efficacy outcome measure was overall survival (OS). Additional efficacy outcome measures were progression-free survival (PFS) and overall response rate (ORR) as assessed by blinded independent central review (BICR). The study population characteristics were: median age of 63 years (range: 25 to 84), 40% age 65 or older; 84% male; 87% White, 13% Asian. Fifteen percent had Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 and 84% had ECOG PS 1; 85% had metastatic disease and 15% had stage IIIB or IIIC disease and were not candidates for surgical resection or definitive chemoradiation per investigator assessment; 57% had non-squamous and 43% had squamous histology; and 7% had history of treated brain metastases at baseline. The trial demonstrated a statistically significant improvement in OS for patients randomized to LIBTAYO in combination with chemotherapy compared with placebo in combination with chemotherapy. Efficacy results are presented in Table 16 and Figure 2. Table 16: Efficacy Results from Study 16113 in Non-Small Cell Lung Cancer Endpoints LIBTAYO and Chemotherapy N=312 Placebo and Chemotherapy N=154 BICR: blinded independent central review; CI: confidence interval; NE: not evaluable; +: ongoing response Overall Survival Deaths, n (%) 132 (42) 82 (53) Median in months (95% CI) Based on Kaplan-Meier method 21.9 (15.5, NE) 13.0 (11.9, 16.1) Hazard ratio (95% CI) Based on stratified proportional hazards model 0.71 (0.53, 0.93) p-value Based on a two-sided p-value 0.0140 Progression-free Survival per BICR Events, n (%) 204 (65) 122 (79) Median in months (95% CI) 8.2 (6.4, 9.3) 5.0 (4.3, 6.2) Hazard ratio (95% CI) 0.56 (0.44, 0.70) p-value <0.0001 Overall Response Rate per BICR (%) ORR (95% CI) Clopper-Pearson exact confidence interval 43 (38, 49) 23 (16, 30) Complete response (CR) rate 2.6 0 Partial response (PR) rate 41 23 p-value <0.0001 Duration of Response per BICR Median in months (range) 15.6 (1.7, 18.7+) 7.3 (1.8, 18.8+) Figure 2: Kaplan-Meier Curve for OS from Study 16113 First-line treatment of NSCLC with LIBTAYO as a single agent The efficacy of LIBTAYO was evaluated in Study 1624 (NCT03088540), a randomized, multi-center, open-label, active-controlled trial in 710 patients with locally advanced NSCLC who were not candidates for surgical resection or definitive chemoradiation, or with metastatic NSCLC. Only patients whose tumors had high PD-L1 expression [Tumor Proportion Score (TPS) ≥50%] as determined by an immunohistochemistry assay using the PD-L1 IHC 22C3 pharmDx kit and who had not received prior systemic treatment for metastatic NSCLC were eligible. Patients with EGFR, ALK or ROS1 genomic tumor aberrations; a medical condition that required systemic immunosuppression; autoimmune disease that required systemic therapy within 2 years of treatment; or who had never smoked were ineligible. Patients with a history of brain metastases were eligible if they had been adequately treated and had neurologically returned to baseline for at least 2 weeks prior to randomization. Randomization was stratified by histology (non-squamous vs squamous) and geographic region (Europe vs Asia vs Rest of world). Patients were randomized (1:1) to receive LIBTAYO 350 mg intravenously (IV) every 3 weeks for up to 108 weeks or a platinum-doublet chemotherapy regimen for 4 to 6 cycles followed by optional pemetrexed maintenance for patients with non-squamous histology who received a pemetrexed containing regimen. Treatment with LIBTAYO continued until RECIST 1.1-defined progressive disease, unacceptable toxicity, or up to 108 weeks. Patients who experienced IRC-assessed RECIST 1.1-defined progressive disease on LIBTAYO therapy were permitted to continue treatment with LIBTAYO (up to an additional 108 weeks) with the addition of 4 cycles of histology-specific chemotherapy until further progression was observed. Of the 203 patients randomized to receive chemotherapy who had IRC-assessed RECIST 1.1- defined disease progression, 150 (74%) patients crossed over to treatment with LIBTAYO. Assessment of tumor status was performed every 9 weeks. The major efficacy outcome measures were overall survival (OS) and progression-free survival (PFS). An additional efficacy outcome measure was overall response rate (ORR). The study population characteristics were: median age of 63 years (range: 31 to 84), 45% age 65 or older; 85% male; 86% White, 11% Asian, and 0.6% Black. Nine percent were Hispanic or Latino. Twenty-seven percent had ECOG PS 0 and 73% had ECOG PS 1; 84% had metastatic disease and 16% had stage IIIB or IIIC disease and were not candidates for surgical resection or definitive chemoradiation per investigator assessment; 56% had non-squamous and 44% had squamous histology; and 12% had history of treated brain metastases at baseline. The trial demonstrated a statistically significant improvement in OS and PFS for patients randomized to LIBTAYO as compared with chemotherapy. Efficacy results are presented in Table 17 and Figure 3. Table 17: Efficacy Results from Study 1624 in Non-Small Cell Lung Cancer Endpoints LIBTAYO N=356 Chemotherapy N=354 BICR: blinded independent central review; CI: confidence interval; NE: not evaluable; +: ongoing response Overall Survival Number of deaths (%) 108 (30) 141 (40) Median in months (95% CI) Based on Kaplan-Meier method 22.1 (17.7, NE) 14.3 (11.7, 19.2) Hazard ratio (95% CI) Based on stratified proportional hazards model 0.68 (0.53, 0.87) p-value 0.0022 Progression-free Survival per BICR Number of events (%) 201 (57) 262 (74) Median in months (95% CI) 6.2 (4.5, 8.3) 5.6 (4.5, 6.1) Hazard ratio (95% CI) 0.59 (0.49, 0.72) p-value <0.0001 Overall Response Rate per BICR (%) Clopper-Pearson exact confidence interval ORR (95% CI) 37 (32, 42) 21 (17, 25) Complete response (CR) rate 3 1 Partial response (PR) rate 33 20 Duration of Response per BICR Median in months (range) 21.0 (1.9+, 23.3+) 6.0 (1.3+, 16.5+) Figure 3: Kaplan-Meier Curve for OS from Study 1624 Figure 2 Figure 3"],"pharmacodynamics":["12.2 Pharmacodynamics Cemiplimab exposure-response relationships and the time course of pharmacodynamic response are not fully characterized."],"pharmacokinetics":["12.3 Pharmacokinetics Cemiplimab-rwlc pharmacokinetics were observed at steady state in patients with various solid tumors and are presented as mean (% coefficient of variation) unless otherwise specified. The pharmacokinetics of cemiplimab-rwlc increase in a dose proportional manner over the dose range of 1 mg/kg to 10 mg/kg (0.2 to 2 times the highest recommended approved dose; assuming a 70 kg patient) administered intravenously every 2 weeks. At a dosing regimen of 350 mg every 3 weeks, cemiplimab-rwlc minimum concentration is 59 mg/L (47%) and maximum concentration is 171 mg/L (27%). Steady-state is reached in about 4 months. At a dosing regimen of 350 mg every 3 weeks for 12 weeks followed by 700 mg every 6 weeks, cemiplimab-rwlc minimum concentration after 30 weeks is 50 mg/L (32%). Distribution The volume of distribution of cemiplimab-rwlc is 5.9 L (29%). Elimination Cemiplimab-rwlc clearance after the first dose is 0.25 L/day (41%) and decreases over time by 11%, resulting in a steady-state clearance of 0.22 L/day (44%). The elimination half-life is 22 days (42%). Specific Populations No clinically significant differences in the pharmacokinetics of cemiplimab-rwlc were observed based on age (27 to 96 years), race [White (N=932), Asian (N=47), Black (N=21)], sex, body weight (31 to 172 kg), cancer type, albumin level (20 to 93 g/L), renal function (creatinine clearance determined by Cockcroft-Gault) and hepatic function (total bilirubin ≥1 to 3× ULN). The effect of severe hepatic impairment (total bilirubin 3× ULN) on the pharmacokinetics of cemiplimab-rwlc is unknown."],"adverse_reactions":["6 ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling. Severe and Fatal Immune-Mediated Adverse Reactions [see Warnings and Precautions (5.1) ] Infusion-Related Reactions [see Warnings and Precautions (5.2) ] Complications of Allogeneic HSCT [see Warnings and Precautions (5.3) ] Most common adverse reactions (≥15%): LIBTAYO as a single agent in mCSCC or laCSCC, m BCC or laBCC, and NSCLC with high PD-L1 expression : Fatigue, musculoskeletal pain, rash, diarrhea, and anemia. ( 6.1 ) LIBTAYO as a single agent in adjuvant CSCC at high risk of recurrence: Rash and pruritus. ( 6.1 ) LIBTAYO in combination with platinum-based chemotherapy in NSCLC: Alopecia, musculoskeletal pain, nausea, fatigue, peripheral neuropathy, and decreased appetite. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Regeneron at 1-877-542-8296 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described in Warnings and Precautions reflect exposure to LIBTAYO as a single agent in 1281 patients with advanced cancers in three open-label, single-arm, multicohort studies, and two open-label randomized multi-center studies. These studies included 384 patients with advanced CSCC (Studies 1540 and 1423), 138 patients with advanced BCC (Study 1620), 355 patients with NSCLC (Study 1624), and 404 patients with other advanced solid tumors. LIBTAYO was administered intravenously at doses of 3 mg/kg every 2 weeks (n=235), 350 mg every 3 weeks (n=1014), or other doses (n=32). Among the 1281 patients, 53% were exposed for 6 months or longer and 26% were exposed for one year or longer. In this pooled safety population, the most common adverse reactions (≥15%) were fatigue, musculoskeletal pain, rash, diarrhea, and anemia. The most common Grade 3-4 laboratory abnormalities (≥2%) were lymphopenia, anemia, hyponatremia, hypophosphatemia, increased aspartate aminotransferase, hypokalemia, hyperkalemia, and increased alanine aminotransferase. The data below also reflect exposure to LIBTAYO as a single agent (either 350 mg every 3 weeks for 12 weeks followed by 700 mg every 6 weeks for 36 weeks or 350 mg every 3 weeks for 48 weeks) in the adjuvant setting in 205 patients with CSCC at high risk of recurrence after treatment with surgery and radiation (C-POST study), and LIBTAYO 350 mg every 3 weeks in combination with platinum-based chemotherapy in 312 patients with NSCLC enrolled in a randomized, active controlled trial (Study 16113). Cutaneous Squamous Cell Carcinoma (CSCC) Study 1540 The safety of LIBTAYO was evaluated in 358 patients with advanced CSCC (metastatic or locally advanced disease) in Study 1540 [see Clinical Studies (14.1) ] . Of these 358 patients, 213 had mCSCC (nodal or distant) and 145 had laCSCC. Patients received LIBTAYO 3 mg/kg every 2 weeks (n=137) or 350 mg every 3 weeks (n=221) as an intravenous infusion until disease progression, unacceptable toxicity, or completion of planned treatment. The median duration of exposure was 40 weeks (1 week to 109 weeks). Serious adverse reactions occurred in 41% of patients. Serious adverse reactions that occurred in at least 2% of patients were pneumonia (3.6%), skin infection (3.6%), and pneumonitis (2.8%). Fatal adverse reactions occurred in 5% of patients who received LIBTAYO, including deaths due to infections (2.2%). Permanent discontinuation due to an adverse reaction occurred in 12% of patients. Adverse reactions resulting in permanent discontinuation in at least 2 patients were pneumonitis, rash, confusional state, general physical health deterioration, hemorrhage, liver function test abnormalities, and musculoskeletal pain. Dosage interruptions of LIBTAYO due to an adverse reaction occurred in 36% of patients. Adverse reactions which required dosage interruption in ≥2% of patients included diarrhea, infusion-related reaction, upper respiratory tract infection, liver function test abnormalities, musculoskeletal pain, pneumonitis, and rash. The most common (≥20%) adverse reactions were fatigue, rash, musculoskeletal pain, diarrhea, pruritus, and nausea. The most common Grade 3 or 4 adverse reactions (≥2%) were hypertension, skin infection, pneumonia, anemia, fatigue, musculoskeletal pain, and pneumonitis. The most common (≥4%) Grade 3 or 4 laboratory abnormalities worsening from baseline were lymphopenia, hyponatremia, anemia, and hypophosphatemia. Table 3 summarizes the adverse reactions that occurred in ≥10% of patients and Table 4 summarizes Grade 3 or 4 laboratory abnormalities worsening from baseline in ≥1% of patients receiving LIBTAYO. Table 3: Adverse Reactions in ≥10% of Patients with Advanced CSCC Receiving LIBTAYO in Study 1540 Adverse Reactions LIBTAYO N = 358 All Grades % Grades 3-4 % Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v.4.03 General and Administration Site Fatigue Fatigue is a composite term that includes fatigue and asthenia 38 2.2 Skin and Subcutaneous Tissue Rash Rash is a composite term that includes rash, rash maculo-papular, dermatitis, erythema, eczema, dermatitis bullous, rash erythematous, dermatitis acneiform, psoriasis, dermatitis contact, blister, pemphigoid, rash papular, hand dermatitis, skin exfoliation, autoimmune dermatitis, rash pruritic, rash macular, rash pustular, urticaria, dermatitis atopic, drug eruption, eczema asteatotic, skin reaction, dermatitis psoriasiform, eczema nummular, exfoliative rash, and immune-mediated dermatitis 34 1.7 Pruritus Pruritus is a composite term that includes pruritus and pruritus allergic 22 0.3 Actinic keratosis 10 0 Musculoskeletal and Connective Tissue Musculoskeletal pain Musculoskeletal pain is a composite term that includes arthralgia, back pain, myalgia, polyarthritis, pain in extremity, neck pain, non-cardiac chest pain, arthritis, musculoskeletal chest pain, musculoskeletal pain, musculoskeletal stiffness, bone pain, immune-mediated arthritis, and spinal pain 33 2.5 Gastrointestinal Diarrhea Diarrhea is a composite term that includes diarrhea, colitis, and autoimmune colitis 26 1.1 Nausea 21 0 Constipation 13 0.3 Vomiting Vomiting is a composite term that includes hematemesis and vomiting 11 0.6 Infections and infestations Upper respiratory tract infection Upper respiratory tract infection is a composite term that includes upper respiratory tract infection, nasopharyngitis, sinusitis, influenza-like illness, rhinitis, influenza, viral upper respiratory tract infection, respiratory tract infection, influenza A virus test positive, and pharyngitis 14 1.1 Skin infection Skin infection is a composite term that includes skin infection, cellulitis, fungal skin infection, and staphylococcal skin infection 11 4.5 Respiratory Cough Cough is a composite term that includes cough, productive cough, and upper airway cough syndrome 12 0 Metabolism and Nutrition Decreased appetite 11 0.6 Nervous system disorders Headache Headache is a composite term that includes headache, sinus headache, and migraine 10 0 Dizziness Dizziness is a composite term that includes dizziness, vertigo, vertigo positional, and dizziness postural 10 0.3 Table 4: Grade 3 or 4 Laboratory Abnormalities Worsening from Baseline in ≥1% of Patients with Advanced CSCC Receiving LIBTAYO in Study 1540 Laboratory Abnormality Grade 3-4 (%) Percentages are based on the number of patients with at least 1 post-baseline value available for that parameter Toxicity graded per NCI CTCAE v. 4.03 Hematology Lymphopenia 7.0 Anemia 4.1 Electrolytes Hyponatremia 4.9 Hypophosphatemia 4.1 Hypercalcemia 2.0 Hypokalemia 1.5 Coagulation Increased INR 2.9 Chemistry Increased aspartate aminotransferase 1.5 Hypoalbuminemia 1.2 Study 1423 In 26 patients with advanced CSCC treated with LIBTAYO in Study 1423 [see Clinical Studies (14.1) ] , safety data were consistent with those described above from Study 1540. Adjuvant treatment of CSCC at high risk of recurrence C-POST study The safety of LIBTAYO was evaluated in patients with CSCC at high-risk of recurrence after surgery and radiation in the C-POST study [see Clinical Studies (14.1) ] . Patients were assigned to receive: LIBTAYO 350 mg (n=140) or placebo (n=140) intravenously every 3 weeks for 12 weeks, followed by 700 mg LIBTAYO or placebo intravenously every 6 weeks for an additional 36 weeks, or LIBTAYO 350 mg every 3 weeks (n=65) or placebo (n=64) for up to 48 weeks. Treatment continued until disease recurrence, unacceptable toxicity, or up to 48 weeks. The median duration of exposure was 48 weeks (range: 3 weeks to 52 weeks) in LIBTAYO-treated patients. Serious adverse reactions occurred in 18% of patients who received LIBTAYO. Serious adverse reactions that occurred in ≥1% of patients in the LIBTAYO arm were pneumonia (1.5%), rash (1.5%), diarrhea (1.5%), adrenal insufficiency (1%), and arrhythmia (1%). Permanent discontinuation due to an adverse reaction occurred in 10% of patients who received LIBTAYO. Adverse reactions resulting in permanent discontinuation in ≥1% of patients were alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, and adrenal insufficiency. Dosage interruptions due to an adverse reaction occurred in 22% of patients who received LIBTAYO. Adverse reactions leading to interruptions in ≥1% of patients included COVID-19, diarrhea, alanine aminotransferase increased, urinary tract infection, upper respiratory tract infection, aspartate aminotransferase increased, edema, dyspnea, pneumonitis, pneumonia, and rash. Table 5 summarizes the adverse reactions that occurred in ≥10% of patients and Table 6 summarizes Grade 3 or 4 laboratory abnormalities worsening from baseline in ≥1% of patients receiving LIBTAYO. Table 5: Adverse Reactions in ≥10% of Patients with CSCC at High Risk of Recurrence in the Adjuvant Setting Receiving LIBTAYO with a Difference Between Arms of ≥3% Compared to Placebo in C-POST study Adverse reactions Toxicity graded per NCI CTCAE v. 5. LIBTAYO N=205 Placebo N=204 All Grades % Grades 3-4 % All Grades % Grades 3-4 % Skin and subcutaneous tissue disorders Rash Includes multiple related terms 37 2 21 0 Pruritus 16 0.5 12 0 Endocrine disorders Hypothyroidism 12 0.5 2.9 0 Table 6: Laboratory Abnormalities Worsening from Baseline in ≥1% of Patients with CSCC at High Risk of Recurrence in the Adjuvant Setting Receiving LIBTAYO in C-POST Study Laboratory Abnormality LIBTAYO Placebo Grade 3-4 (%) The denominator used to calculate the rate varied from 201 to 203 based on the number of patients with a baseline value and at least one post-treatment value. Toxicity graded per NCI CTCAE v. 5 Hematology Lymphocyte count decreased 6 3 Chemistry Alanine aminotransferase increased 3.9 0 Aspartate aminotransferase increased 3 0.5 Alkaline phosphatase increased 1.5 0 Albumin decreased 1 0 Electrolytes Calcium decreased 1 1 Potassium decreased 1 0.5 Basal Cell Carcinoma (BCC) The safety of LIBTAYO was evaluated in 138 patients with advanced BCC (mBCC N=54, laBCC N=84) in an open-label, single-arm trial (Study 1620) [see Clinical Studies (14.2) ] . Patients received LIBTAYO 350 mg every 3 weeks as an intravenous infusion for up to 93 weeks or until disease progression or unacceptable toxicity. The median duration of exposure was 45 weeks (range: 2.1 weeks to 98 weeks). Serious adverse reactions occurred in 34% of patients. Serious adverse reactions that occurred in > 1.5% were diarrhea (3.6%), urinary tract infection (3.6%), pneumonia (2.9%), and hemorrhage (2.2%). Fatal adverse reactions occurred in 4.3% of patients who received LIBTAYO, including acute kidney injury (0.7%) and cachexia worsening due to colitis (0.7%). Permanent discontinuation of LIBTAYO due to an adverse reaction occurred in 14% of patients. Adverse reactions resulting in permanent discontinuation of LIBTAYO in at least 2 patients were diarrhea, acute kidney injury, general physical health deterioration, and hepatitis. Dosage interruptions of LIBTAYO due to an adverse reaction occurred in 40% of patients. Adverse reactions which required dosage interruptions in > 2% of patients included diarrhea, musculoskeletal pain, acute kidney injury, fatigue, fall, headache, infusion-related reaction, hemorrhage, pneumonitis, upper respiratory tract infection, and urinary tract infection. The most common adverse reactions reported in at least 15% of patients were fatigue, musculoskeletal pain, diarrhea, rash, upper respiratory tract infection, pruritus, hemorrhage, and hypertension. The most common Grade 3 or 4 adverse reactions (> 2%) were hypertension, diarrhea, fatigue, musculoskeletal pain, hypokalemia, hyponatremia, pneumonia, urinary tract infection, visual impairment, and weight decreased. The most common (> 2%) laboratory abnormalities worsening from baseline to Grade 3 or 4 were lymphopenia and hyponatremia. Table 7 summarizes the adverse reactions that occurred in ≥10% of patients and Table 8 summarizes Grade 3 or 4 laboratory abnormalities worsening from baseline in ≥1% of patients receiving LIBTAYO. Table 7: Adverse Reactions in ≥10% of Patients with Advanced BCC Receiving LIBTAYO in Study 1620 Adverse Reactions LIBTAYO N = 138 All Grades % Grades 3-4 % Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v.4.03 General disorders and administration site conditions Fatigue Fatigue is a composite term that includes fatigue, asthenia, and malaise 50 4.3 Edema Edema is a composite term that includes peripheral edema, peripheral swelling, and face swelling 10 0.7 Musculoskeletal and connective tissue disorders Musculoskeletal pain Musculoskeletal pain is a composite term that includes arthralgia, back pain, pain in extremity, myalgia, neck pain, non-cardiac chest pain, arthritis, musculoskeletal chest pain, musculoskeletal stiffness, musculoskeletal discomfort, and spinal pain 36 2.9 Gastrointestinal disorders Diarrhea Diarrhea is a composite term that includes diarrhea, colitis, autoimmune colitis, and enterocolitis 33 4.3 Nausea 13 0.7 Abdominal pain Abdominal pain is a composite term that includes abdominal pain, abdominal pain upper, abdominal pain lower, and gastrointestinal pain 12 1.4 Constipation 12 0.7 Skin and subcutaneous tissue disorders Rash Rash is a composite term that includes rash maculo-papular, eczema, rash, dermatitis, erythema, dermatitis acneiform, rash pruritic, rash pustular, dermatitis bullous, dyshidrotic eczema, pemphigoid, rash erythematous, urticaria, nodular rash, and skin exfoliation 30 0.7 Pruritus 19 0 Infections and infestations Upper respiratory tract infection Upper respiratory tract infection is a composite term that includes upper respiratory tract infection, influenza-like illness, nasopharyngitis, rhinitis, sinusitis, viral rhinitis, pharyngitis, laryngitis, respiratory tract infection, influenza, viral upper respiratory tract infection, and influenza A virus test positive 22 0 Urinary tract infection Urinary tract infection is a composite term that includes urinary tract infection, cystitis, and urosepsis 13 2.2 Vascular disorders Hemorrhage Hemorrhage is a composite term that includes tumor hemorrhage, hematuria, epistaxis, eye hemorrhage, hemoptysis, hemorrhage intracranial, hemorrhagic diathesis, postmenopausal hemorrhage, rectal hemorrhage, skin hemorrhage, skin neoplasm bleeding, ulcer hemorrhage, vaginal hemorrhage, wound hemorrhage, and subcutaneous hematoma 18 0.7 Hypertension Hypertension is a composite term that includes hypertension, blood pressure increased, and hypertensive crisis 17 9 Metabolism and nutrition disorders Decreased appetite 14 1.4 Blood and lymphatic system disorders Anemia 14 0.7 Respiratory, thoracic, and mediastinal disorders Dyspnea Dyspnea is a composite term that includes dyspnea and dyspnea exertional 14 0 Renal and urinary disorders Acute kidney injury Acute kidney injury is a composite term that includes blood creatinine increased, acute kidney injury, renal failure, renal impairment, glomerular filtration rate decreased, and nephropathy toxic 14 0 Nervous system disorders Headache 13 1.4 Dizziness Dizziness is a composite term that includes dizziness and vertigo 12 0 Peripheral neuropathy Peripheral neuropathy is a composite term that includes paresthesia, dysesthesia, hypoesthesia, peripheral motor neuropathy, burning sensation, neuralgia, and peripheral sensory neuropathy 11 0 Endocrine disorders Hypothyroidism Hypothyroidism is a composite term that includes hypothyroidism, blood thyroid stimulating hormone increased, and immune-mediated hypothyroidism 12 0 Investigations Liver function test abnormalities Liver function test abnormalities is a composite term that includes alanine aminotransferase increased, aspartate aminotransferase increased, bilirubin conjugated increased, blood alkaline phosphatase increased, blood bilirubin increased, and gamma-glutamyl transferase increased 10 1.4 Table 8: Grade 3 or 4 Laboratory Abnormalities Worsening from Baseline in ≥1% of Patients with Advanced BCC Receiving LIBTAYO in Study 1620 Laboratory Abnormality Grade 3-4 (%) Percentages are based on the number of patients with at least 1 post-baseline value available for that parameter Toxicity graded per NCI CTCAE v. 4.03 Hematology Lymphopenia 2.9 Electrolytes Hyponatremia 2.9 Hypokalemia 1.5 Coagulation Activated partial thromboplastin time prolonged 1.9 Non-Small Cell Lung Cancer (NSCLC) First-line treatment of NSCLC with LIBTAYO in Combination with Platinum-based Chemotherapy The safety of LIBTAYO in combination with platinum-based chemotherapy was evaluated in 465 patients with locally advanced or metastatic NSCLC in Study 16113 [see Clinical Studies (14.3) ]. Patients received LIBTAYO 350 mg every 3 weeks plus platinum-based chemotherapy every 3 weeks for 4 cycles (n=312), or placebo every 3 weeks plus platinum-based chemotherapy every 3 weeks for 4 cycles (n=153). Among patients who received LIBTAYO, 70% were exposed for 6 months or longer and 35% were exposed for greater than one year. The safety population characteristics were: median age of 63 years (25 to 82 years), 41% of patients 65 or older, 86% male, 86% White, 14% Asian, 86% had metastatic disease and 14% had locally advanced disease and Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 (16%) and 1 (83%). Serious adverse reactions occurred in 25% of patients. The most frequent serious adverse reactions that occurred in at least 2% of patients were pneumonia, anemia, and neutropenia. Fatal adverse reactions occurred in 6% of patients who received LIBTAYO in combination with chemotherapy, including death not otherwise specified (2.9%), sudden death (1.0%), acute hepatitis (0.3%), acute respiratory distress syndrome (0.3%), mesenteric artery thrombosis (0.3%), pneumonia (0.3%), pneumonitis (0.3%), and pulmonary hemorrhage (0.3%). LIBTAYO was permanently discontinued due to adverse reactions in 5% of patients. Adverse reactions resulting in permanent discontinuation in at least 2 patients were increased alanine aminotransferase and anemia. Dosage interruptions of LIBTAYO due to an adverse reaction occurred in 33% of patients. Adverse reactions which required dosage interruptions in at least 2% of patients were anemia, pneumonia, neutropenia, thrombocytopenia, fatigue, COVID-19 infection, and pyrexia. The most common (≥15%) adverse reactions were alopecia, musculoskeletal pain, nausea, fatigue, peripheral neuropathy, and decreased appetite. The most common Grade 3-4 laboratory abnormalities (≥2%) were anemia, neutropenia, lymphopenia, leukopenia, hyponatremia, thrombocytopenia, hyperglycemia, hypophosphatemia, increased alanine aminotransferase, hypocalcemia, hyperkalemia, hypermagnesemia, hypokalemia, and increased creatinine. Table 9 summarizes the adverse reactions that occurred in ≥10% of patients and Table 10 summarizes Grade 3 or 4 laboratory abnormalities in patients receiving LIBTAYO and chemotherapy. Table 9: Adverse Reactions in ≥10% of Patients with Locally Advanced or Metastatic NSCLC Receiving LIBTAYO and Chemotherapy in Study 16113 Adverse Reactions LIBTAYO and Chemotherapy (N=312) Placebo and Chemotherapy (N=153) All Grades % Grades 3 or 4 % All Grades % Grades 3 or 4 % Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v. 4.03 Skin and subcutaneous tissue disorders Alopecia 37 0 43 0 Rash Rash is a composite term that includes rash, rash maculo-papular, dermatitis, psoriasis, rash papular, urticaria, dermatitis allergic, erythema, lichen planus, rash macular, rash pruritic, skin reaction, skin toxicity, skin exfoliation, and dermatitis acneiform 13 1.3 6 0 Musculoskeletal and connective tissue disorders Musculoskeletal pain Musculoskeletal pain is a composite term that includes arthralgia, back pain, pain in extremity, non-cardiac chest pain, myalgia, bone pain, musculoskeletal pain, neck pain, musculoskeletal chest pain, arthritis, and spinal pain 30 1.6 36 0 Gastrointestinal disorders Nausea 25 0 16 0 Constipation 14 0.3 11 0 Vomiting 12 0 10 0 Diarrhea 11 1.3 7 0 General disorders and administration site conditions Fatigue Fatigue is a composite term that includes asthenia, fatigue, and malaise 23 3.8 18 2 Nervous system disorders Peripheral neuropathy Peripheral neuropathy is a composite term that includes peripheral sensory neuropathy, peripheral neuropathy, paresthesia, polyneuropathy, hypoesthesia, peripheral sensorimotor neuropathy, neuralgia, polyneuropathy in malignant disease, and toxic neuropathy 23 0 19 0 Metabolism and nutrition disorders Decreased appetite 17 1 12 0 Investigations Weight decreased 11 1.3 8 0 Respiratory, thoracic, and mediastinal disorders Dyspnea Dyspnea is a composite term that includes dyspnea and dyspnea exertional 13 2.2 7 0.7 Psychiatric disorders Insomnia 11 0 7 0 Table 10: Grade 3 or 4 Laboratory Abnormalities Worsening from Baseline in ≥1% of Patients with Locally Advanced or Metastatic NSCLC Receiving LIBTAYO and Chemotherapy in Study 16113 Laboratory Abnormality LIBTAYO and Chemotherapy Placebo and Chemotherapy Grades 3 or 4 (%) The denominator used to calculate the rate varied from 134 to 299 based on the number of patients with a baseline value and at least one post-treatment value. Toxicity graded per NCI CTCAE v. 4.03 Chemistry Hyperglycemia 4 1.5 Increased alanine aminotransferase 3 2.1 Increased creatinine 2 1.4 Hypoalbuminemia 1 0 Hematology Anemia 10 7 Neutrophil count decreased 10 8 Lymphocyte count decreased 7 8 White blood cell decreased 6 4.1 Platelet count decreased 4.7 0.7 Electrolytes Hyponatremia 6 4.1 Hypophosphatemia 3.4 7 Hypocalcemia 3 2.1 Hyperkalemia 2.7 2.7 Hypermagnesemia 2.4 2.8 Hypokalemia 2.3 1.4 Hypercalcemia 1.7 0.7 Hypernatremia 1 0 First-line treatment of NSCLC with LIBTAYO as a single agent The safety of LIBTAYO was evaluated in 355 patients with locally advanced or metastatic NSCLC in Study 1624 [see Clinical Studies (14.3) ]. Patients received LIBTAYO 350 mg every 3 weeks (n=355) or investigator's choice of chemotherapy (n=342), consisting of paclitaxel plus cisplatin or carboplatin; gemcitabine plus cisplatin or carboplatin; or pemetrexed plus cisplatin or carboplatin followed by optional pemetrexed maintenance. The median duration of exposure was 27.3 weeks (9 days to 115 weeks) in the LIBTAYO group and 17.7 weeks (18 days to 86.7 weeks) in the chemotherapy group. In the LIBTAYO group, 54% of patients were exposed to LIBTAYO for ≥6 months and 22% were exposed for ≥12 months. The safety population characteristics were: median age of 63 years (31 to 79 years), 44% of patients 65 or older, 88% male, 86%White, 82% had metastatic disease and 18% had locally advanced disease, and ECOG performance score (PS) of 0 (27%) and 1 (73%). LIBTAYO was permanently discontinued due to adverse reactions in 6% of patients; adverse reactions resulting in permanent discontinuation in at least 2 patients were pneumonitis, pneumonia, ischemic stroke, and increased aspartate aminotransferase. Serious adverse reactions occurred in 28% of patients. The most frequent serious adverse reactions in at least 2% of patients were pneumonia and pneumonitis. Table 11 summarizes the adverse reactions that occurred in ≥10% of patients and Table 12 summarizes Grade 3 or 4 laboratory abnormalities in patients receiving LIBTAYO. Table 11: Adverse Reactions in ≥10% of Patients with Locally Advanced or Metastatic NSCLC Receiving LIBTAYO in Study 1624 Adverse Reactions LIBTAYO N=355 Chemotherapy N=342 All Grades % Grades 3-4 % All Grades % Grades 3-4 % Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v.4.03 Musculoskeletal and connective tissue disorders Musculoskeletal pain Musculoskeletal pain is a composite term that includes back pain, arthralgia, pain in extremity, musculoskeletal pain, musculoskeletal chest pain, bone pain, myalgia, neck pain, spinal pain, and musculoskeletal stiffness 26 0.6 27 1.5 Skin and subcutaneous tissue disorders Rash Rash is a composite term that includes rash, dermatitis, urticaria, rash maculo-papular, erythema, rash erythematous, rash pruritic, psoriasis, autoimmune dermatitis, dermatitis acneiform, dermatitis allergic, dermatitis atopic, dermatitis bullous, drug eruption, dyshidrotic eczema, lichen planus, and skin reaction 15 1.4 6 0 Blood and lymphatic system disorders Anemia 15 3.4 50 16 General disorders and administration site conditions Fatigue Fatigue is a composite term that includes fatigue, asthenia, and malaise 14 1.1 26 2 Metabolism and nutrition disorders Decreased appetite 12 0.6 18 0.3 Infections and infestations Pneumonia Pneumonia is a composite term that includes atypical pneumonia, embolic pneumonia, lower respiratory tract infection, lung abscess, paracancerous pneumonia, pneumonia, pneumonia bacterial, and pneumonia klebsiella 11 5 12 5 Respiratory, thoracic, and mediastinal disorders Cough Cough is a composite term that includes cough and productive cough 11 0 8 0.3 Table 12: Grade 3 or 4 Laboratory Abnormalities Worsening from Baseline in ≥1% of Patients with Locally Advanced or Metastatic NSCLC Receiving LIBTAYO in Study 1624 Laboratory Abnormality LIBTAYO N=355 Chemotherapy N=342 Grades 3-4 Percentages are based on the number of patients with at least 1 post-baseline value available for that parameter % Toxicity graded per NCI CTCAE v. 4.03 Chemistry Increased aspartate aminotransferase 3.9 1.2 Increased alanine aminotransferase 2.7 0.3 Increased alkaline phosphatase 2.4 0.3 Increased blood bilirubin 2.1 0.3 Hypoalbuminemia 1.8 1.3 Increased creatinine 1.2 1.6 Hematology Lymphopenia 7 9 Anemia 2.7 16 Electrolytes Hyponatremia 6 7 Hyperkalemia 4.2 1.9 Hypocalcemia 3.9 3.4 Hypophosphatemia 2.4 4.1 Hypermagnesemia 2.1 1.6 Hypokalemia 1.5 2.2 Hypercalcemia 1.2 2.2"],"contraindications":["4 CONTRAINDICATIONS None. None. ( 4 )"],"spl_medguide_table":["<table width=\"100%\"><col width=\"20%\" align=\"left\" valign=\"top\"/><col width=\"20%\" align=\"left\" valign=\"top\"/><col width=\"20%\" align=\"left\" valign=\"top\"/><col width=\"40%\" align=\"left\" valign=\"top\"/><tfoot><tr><td align=\"left\" colspan=\"3\">This Medication Guide has been approved by the U.S. Food and Drug Administration.</td><td align=\"right\">Revised: October 2025 </td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\" align=\"center\"><content styleCode=\"bold\">MEDICATION GUIDE</content>  LIBTAYO<sup>&#xAE;</sup> (Lib-TIE-oh)   (cemiplimab-rwlc)   injection</td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content ID=\"What\" styleCode=\"bold\">What is the most important information I should know about LIBTAYO?</content>  LIBTAYO is a medicine that may treat certain types of cancers by working with your immune system. LIBTAYO can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.  <content styleCode=\"bold\">Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:   Lung problems.</content></td></tr><tr><td styleCode=\"Lrule\"><list listType=\"unordered\" styleCode=\"disc\"><item>cough</item></list></td><td><list listType=\"unordered\" styleCode=\"disc\"><item>shortness of breath</item></list></td><td/><td styleCode=\"Rrule\"><list listType=\"unordered\" styleCode=\"disc\"><item>chest pain</item></list></td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">Intestinal problems.</content><list listType=\"unordered\" styleCode=\"disc\"><item>diarrhea (loose stools) or more frequent bowel movements than usual</item><item>stools that are black, tarry, sticky, or have blood or mucus</item><item>severe stomach-area (abdomen) pain or tenderness</item></list></td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">Liver problems.</content></td></tr><tr><td styleCode=\"Lrule\" colspan=\"2\"><list listType=\"unordered\" styleCode=\"disc\"><item>yellowing of your skin or the whites of your eyes</item><item>severe nausea or vomiting</item><item>pain on the right side of your stomach-area (abdomen)</item></list></td><td styleCode=\"Rrule\" colspan=\"2\"><list listType=\"unordered\" styleCode=\"disc\"><item>dark urine (tea colored)</item><item>bleeding or bruising more easily than normal</item></list></td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">Hormone gland problems.</content></td></tr><tr><td styleCode=\"Lrule\" colspan=\"2\"><list listType=\"unordered\" styleCode=\"disc\"><item>headache that will not go away or unusual headaches</item><item>eye sensitivity to light</item><item>eye problems</item><item>rapid heartbeat</item><item>increased sweating</item><item>extreme tiredness</item><item>weight gain or weight loss</item><item>feeling more hungry or thirsty than usual</item></list></td><td styleCode=\"Rrule\" colspan=\"2\"><list listType=\"unordered\" styleCode=\"disc\"><item>urinating more often than usual</item><item>hair loss</item><item>feeling cold</item><item>constipation</item><item>your voice gets deeper</item><item>dizziness or fainting</item><item>changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness</item></list></td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">Kidney problems.</content></td></tr><tr><td styleCode=\"Lrule\" colspan=\"2\"><list listType=\"unordered\" styleCode=\"disc\"><item>decrease in your amount of urine</item><item>blood in your urine</item></list></td><td styleCode=\"Rrule\" colspan=\"2\"><list listType=\"unordered\" styleCode=\"disc\"><item>swelling of your ankles</item><item>loss of appetite</item></list></td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">Skin problems.</content></td></tr><tr><td styleCode=\"Lrule\" colspan=\"2\"><list listType=\"unordered\" styleCode=\"disc\"><item>rash</item><item>itching</item><item>skin blistering or peeling</item></list></td><td styleCode=\"Rrule\" colspan=\"2\"><list listType=\"unordered\" styleCode=\"disc\"><item>painful sores or ulcers in mouth or nose, throat, or genital area</item><item>fever or flu-like symptoms</item><item>swollen lymph nodes</item></list></td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with LIBTAYO. Call or see your healthcare provider right away for any new or worsening signs or symptoms which may include:</content><list listType=\"unordered\" styleCode=\"disc\"><item>chest pain, irregular heartbeat, shortness of breath or swelling of ankles</item><item>confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs</item><item>double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight</item><item>persistent or severe muscle pain or weakness, muscle cramps</item><item>low red blood cells, bruising</item></list></td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">Infusion reactions that can sometimes be severe or life-threatening.</content> Signs and symptoms of infusion reactions may include:</td></tr><tr><td styleCode=\"Lrule\" colspan=\"2\"><list listType=\"unordered\" styleCode=\"disc\"><item>nausea</item><item>vomiting</item><item>chills or shaking</item><item>itching or rash</item><item>flushing</item><item>shortness of breath or wheezing</item></list></td><td styleCode=\"Rrule\" colspan=\"2\"><list listType=\"unordered\" styleCode=\"disc\"><item>dizziness</item><item>feel like passing out</item><item>fever</item><item>back or neck pain</item><item>facial swelling</item></list></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">Rejection of a transplanted organ or tissue.</content> Your healthcare provider should tell you what signs and symptoms you should report and monitor you, depending on the type of organ or tissue transplant that you have had.  <content styleCode=\"bold\">Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic).</content> These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with LIBTAYO. Your healthcare provider will monitor you for these complications.  <content styleCode=\"bold\">Getting medical treatment right away may help keep these problems from becoming more serious.</content> Your healthcare provider will check you for these problems during your treatment with LIBTAYO. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with LIBTAYO if you have severe side effects.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">What is LIBTAYO?</content>  LIBTAYO is a prescription medicine used to treat adults with: <list listType=\"unordered\" styleCode=\"disc\"><item>a type of skin cancer called cutaneous squamous cell carcinoma (CSCC). <list listType=\"unordered\" styleCode=\"circle\"><item>LIBTAYO may be used: <list listType=\"unordered\" styleCode=\"square\"><item>to treat CSCC that has spread or cannot be cured by surgery or radiation, <content styleCode=\"bold\">or</content></item><item>to help prevent CSCC from coming back if your CSCC is at high risk of coming back after it has been removed by surgery and radiation.</item></list></item></list></item><item>a type of skin cancer called basal cell carcinoma (BCC). <list listType=\"unordered\" styleCode=\"circle\"><item>LIBTAYO may be used when your BCC cannot be removed by surgery (locally advanced BCC) or when it has spread (metastatic BCC), <content styleCode=\"bold\">and</content><list listType=\"unordered\" styleCode=\"square\"><item>you have previously received treatment with a hedgehog pathway inhibitor (HHI), <content styleCode=\"bold\">or</content></item><item>you cannot receive treatment with a HHI.</item></list></item></list></item><item>a type of lung cancer called non-small cell lung cancer (NSCLC). <list listType=\"unordered\" styleCode=\"circle\"><item>LIBTAYO may be used in combination with chemotherapy that contains a platinum medicine as your first treatment when your lung cancer: <list listType=\"unordered\" styleCode=\"suare\"><item>has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, <content styleCode=\"bold\">or</content></item><item>your lung cancer has spread to other areas of your body (metastatic lung cancer), <content styleCode=\"bold\">and</content></item><item>your tumor does not have an abnormal &quot;EGFR&quot;, &quot;ALK&quot; or &quot;ROS1&quot; gene.</item></list></item><item>LIBTAYO may be used alone as your first treatment when your lung cancer: <list listType=\"unordered\" styleCode=\"suare\"><item>has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, <content styleCode=\"bold\">or</content></item><item>your lung cancer has spread to other areas of your body (metastatic lung cancer), <content styleCode=\"bold\">and</content></item><item>your tumor tests positive for high &quot;PD-L1&quot; <content styleCode=\"bold\">and</content></item><item>your tumor does not have an abnormal &quot;EGFR&quot;, &quot;ALK&quot; or &quot;ROS1&quot; gene</item></list></item></list></item></list> It is not known if LIBTAYO is safe and effective in children.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">Before you receive LIBTAYO, tell your healthcare provider about all your medical conditions, including if you:</content><list listType=\"unordered\" styleCode=\"disc\"><item>have immune system problems such as Crohn&apos;s disease, ulcerative colitis, or lupus</item><item>have received an organ or tissue transplant, including corneal transplant</item><item>have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)</item><item>have received radiation treatment to your chest area</item><item>have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barr&#xE9; syndrome</item><item>are pregnant or plan to become pregnant. LIBTAYO can harm your unborn baby.  <content styleCode=\"bold\">Females who are able to become pregnant:</content><list listType=\"unordered\" styleCode=\"circle\"><item>Your healthcare provider will give you a pregnancy test before you start treatment with LIBTAYO.</item><item>You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of LIBTAYO. Talk to your healthcare provider about birth control methods that you can use during this time.</item><item>Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with LIBTAYO.</item></list></item><item>are breastfeeding or plan to breastfeed. It is not known if LIBTAYO passes into your breast milk. Do not breastfeed during treatment and for at least 4 months after the last dose of LIBTAYO.</item></list><content styleCode=\"bold\">Tell your healthcare provider about all the medicines you take</content><content styleCode=\"italics\">,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">How will I receive LIBTAYO?</content><list listType=\"unordered\" styleCode=\"disc\"><item>Your healthcare provider will give you LIBTAYO into your vein through an intravenous (IV) line over 30 minutes.</item><item>LIBTAYO is usually given every 3 weeks or every 6 weeks depending on the dose of LIBTAYO you are receiving.</item><item>Your healthcare provider will decide how many treatments you will need.</item><item>Your healthcare provider will do blood tests to check you for side effects.</item></list> If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.</td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">What are the possible side effects of LIBTAYO?   LIBTAYO can cause serious side effects.</content><list listType=\"unordered\" styleCode=\"disc\"><item><content styleCode=\"bold\">See &quot;<linkHtml href=\"#What\">What is the most important information I should know about LIBTAYO?</linkHtml>&quot;</content></item></list></td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"4\">The most common side effects of LIBTAYO when used alone to treat CSCC that has spread or cannot be cured by surgery or radiation, BCC or NSCLC include:</td></tr><tr><td styleCode=\"Lrule\" colspan=\"2\"><list listType=\"unordered\" styleCode=\"disc\"><item>tiredness</item><item>muscle or bone pain</item><item>rash</item></list></td><td styleCode=\"Rrule\" colspan=\"2\"><list listType=\"unordered\" styleCode=\"disc\"><item>diarrhea</item><item>low levels of red blood cells (anemia)</item></list></td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"4\">The most common side effects of LIBTAYO when used alone to help prevent CSCC from coming back include: <list listType=\"unordered\" styleCode=\"disc\"><item>rash</item><item>itching</item></list></td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"4\">The most common side effects of LIBTAYO when used in combination with platinum-containing chemotherapy to treat NSCLC include:</td></tr><tr><td styleCode=\"Lrule\" colspan=\"2\"><list listType=\"unordered\" styleCode=\"disc\"><item>hair loss</item><item>muscle or bone pain</item><item>nausea</item></list></td><td styleCode=\"Rrule\" colspan=\"2\"><list listType=\"unordered\" styleCode=\"disc\"><item>tiredness</item><item>numbness, pain, tingling or burning in your hands or feet</item><item>decreased appetite</item></list></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\">These are not all the possible side effects of LIBTAYO.   Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">General information about the safe and effective use of LIBTAYO.</content>  Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about LIBTAYO that is written for health professionals.</td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">What are the ingredients of LIBTAYO?</content>  Active ingredient: cemiplimab-rwlc   Inactive ingredients: L-histidine, L-histidine monohydrochloride monohydrate, sucrose, L-proline, Polysorbate 80, and Water for Injection.   Manufactured by: Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 U.S. License No. 1760   Marketed by: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591)   For more information, call 1-877-542-8296   &#xA9;2025 Regeneron Pharmaceuticals, Inc.   All rights reserved.</td></tr></tbody></table>"],"mechanism_of_action":["12.1 Mechanism of Action Binding of the PD-1 ligands PD-L1 and PD-L2 to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Cemiplimab-rwlc is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth."],"recent_major_changes":["Indications and Usage ( 1.1 ) 10/2025 Dosage and Administration ( 2.2 ) 10/2025"],"storage_and_handling":["Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton. Protect from light. Do not freeze or shake."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Binding of the PD-1 ligands PD-L1 and PD-L2 to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Cemiplimab-rwlc is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth. 12.2 Pharmacodynamics Cemiplimab exposure-response relationships and the time course of pharmacodynamic response are not fully characterized. 12.3 Pharmacokinetics Cemiplimab-rwlc pharmacokinetics were observed at steady state in patients with various solid tumors and are presented as mean (% coefficient of variation) unless otherwise specified. The pharmacokinetics of cemiplimab-rwlc increase in a dose proportional manner over the dose range of 1 mg/kg to 10 mg/kg (0.2 to 2 times the highest recommended approved dose; assuming a 70 kg patient) administered intravenously every 2 weeks. At a dosing regimen of 350 mg every 3 weeks, cemiplimab-rwlc minimum concentration is 59 mg/L (47%) and maximum concentration is 171 mg/L (27%). Steady-state is reached in about 4 months. At a dosing regimen of 350 mg every 3 weeks for 12 weeks followed by 700 mg every 6 weeks, cemiplimab-rwlc minimum concentration after 30 weeks is 50 mg/L (32%). Distribution The volume of distribution of cemiplimab-rwlc is 5.9 L (29%). Elimination Cemiplimab-rwlc clearance after the first dose is 0.25 L/day (41%) and decreases over time by 11%, resulting in a steady-state clearance of 0.22 L/day (44%). The elimination half-life is 22 days (42%). Specific Populations No clinically significant differences in the pharmacokinetics of cemiplimab-rwlc were observed based on age (27 to 96 years), race [White (N=932), Asian (N=47), Black (N=21)], sex, body weight (31 to 172 kg), cancer type, albumin level (20 to 93 g/L), renal function (creatinine clearance determined by Cockcroft-Gault) and hepatic function (total bilirubin ≥1 to 3× ULN). The effect of severe hepatic impairment (total bilirubin 3× ULN) on the pharmacokinetics of cemiplimab-rwlc is unknown. 12.6 Immunogenicity The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of cemiplimab-rwlc or of other cemiplimab products. During a treatment period ranging from 8 to 19 months in 5 clinical studies, 2% (22/1029) of LIBTAYO-treated patients developed anti-cemiplimab-rwlc antibodies. There was no clinically significant effect of anti-cemiplimab-rwlc antibodies on PK of cemiplimab-rwlc. Because of the low occurrence of anti-drug antibodies, the effect of these antibodies on the pharmacodynamics, safety, and/or effectiveness of cemiplimab products is unknown."],"indications_and_usage":["1 INDICATIONS AND USAGE LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) for the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. ( 1.1 ) for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation. ( 1.1 , 14.1 ) Basal Cell Carcinoma (BCC) for the treatment of adult patients with locally advanced or metastatic BCC (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. ( 1.2 ) Non-Small Cell Lung Cancer (NSCLC) in combination with platinum‐based chemotherapy for the first‐line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 ) as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 , 2.1 ) 1.1 Cutaneous Squamous Cell Carcinoma LIBTAYO is indicated for the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. LIBTAYO is indicated for the adjuvant treatment of adult patients with CSCC at high risk of recurrence [see Clinical Studies (14.1) ] after surgery and radiation . 1.2 Basal Cell Carcinoma LIBTAYO is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. 1.3 Non-Small Cell Lung Cancer LIBTAYO in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. LIBTAYO as a single agent is indicated for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥50%] as determined by an FDA-approved test [see Dosage and Administration (2.1) ] , with no EGFR, ALK or ROS1 aberrations, and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Immune-Mediated Adverse Reactions ( 5.1 ) Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, including the following: immune-mediated pneumonitis, immune-mediated colitis, immune-mediated hepatitis, immune-mediated endocrinopathies, immune-mediated dermatologic adverse reactions, immune-mediated nephritis and renal dysfunction, and solid organ transplant rejection. Monitor for early identification and management. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. Withhold or permanently discontinue LIBTAYO based on the severity of reaction. ( 2.3 ) Infusion-Related Reactions: Interrupt, slow the rate of infusion, or permanently discontinue based on severity of reaction. ( 2.3 , 5.2 ) Complications of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after being treated with a PD-1/PD-L1 blocking antibody. ( 5.3 ) Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and use of effective contraception. ( 5.4 , 8.1 , 8.3 ) 5.1 Severe and Fatal Immune-Mediated Adverse Reactions LIBTAYO is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death receptor-1 (PD-1) or PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Important immune-mediated adverse reactions listed under Warnings and Precautions may not include all possible severe and fatal immune-mediated reactions. The incidence and severity of immune-mediated adverse reactions were similar when LIBTAYO was administered as a single agent or in combination with chemotherapy. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. Immune-mediated adverse reactions can occur at any time after starting PD-1/PD-L1 blocking antibody. While immune-mediated adverse reactions usually manifest during treatment with PD-1/PD-L1 blocking antibodies, immune-mediated adverse reactions can also manifest after discontinuation of PD-1/PD-L1 blocking antibodies. Immune-mediated adverse reactions affecting more than one body system can occur simultaneously. Early identification and management of immune‐mediated adverse reactions are essential to ensure safe use of PD-1/PD-L1 blocking antibodies. Monitor closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate. Withhold or permanently discontinue LIBTAYO depending on severity [see Dosage and Administration (2.3) ] . In general, if LIBTAYO requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroids. Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g., endocrinopathies and dermatologic reactions) are discussed below. Immune-Mediated Pneumonitis LIBTAYO can cause immune-mediated pneumonitis. The definition of immune-mediated pneumonitis included the required use of systemic corticosteroids or other immunosuppressants and the absence of a clear alternate etiology. In patients treated with other PD-1/PD-L1 blocking antibodies the incidence of pneumonitis is higher in patients who have received prior thoracic radiation. Immune-mediated pneumonitis occurred in 2.6% (33/1281) of patients receiving LIBTAYO, including Grade 4 (0.3%), Grade 3 (0.6%), and Grade 2 (1.6%) adverse reactions. Pneumonitis led to permanent discontinuation of LIBTAYO in 1.3% of patients and withholding of LIBTAYO in 1.4% of the patients. Systemic corticosteroids were required in all patients with pneumonitis. Pneumonitis resolved in 61% of the 33 patients. Of the 18 patients in whom LIBTAYO was withheld for pneumonitis, 10 reinitiated LIBTAYO after symptom improvement; of these, 4/10 (40%) had recurrence of pneumonitis. Immune-Mediated Colitis LIBTAYO can cause immune-mediated colitis. The definition of immune-mediated colitis included the required use of systemic corticosteroids or other immunosuppressants and the absence of a clear alternate etiology. The primary component of the immune-mediated colitis was diarrhea. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis treated with PD-1/PD-L1 blocking antibodies. In cases of corticosteroid refractory colitis, consider repeating infectious workup to exclude alternative etiologies. Immune-mediated colitis occurred in 2% (25/1281) of patients receiving LIBTAYO, including Grade 3 (0.8%) and Grade 2 (0.9%) adverse reactions. Colitis led to permanent discontinuation of LIBTAYO in 0.4% of patients and withholding of LIBTAYO in 1.2% of patients. Systemic corticosteroids were required in all patients with colitis. Colitis resolved in 56% of the 25 patients. Of the 16 patients in whom LIBTAYO was withheld for colitis, 6 reinitiated LIBTAYO after symptom improvement; of these, 4/6 (67%) had recurrence of colitis. Immune-Mediated Hepatitis LIBTAYO can cause immune-mediated hepatitis. The definition of immune-mediated hepatitis included the required use of systemic corticosteroids or other immunosuppressants and the absence of a clear alternate etiology. Immune-mediated hepatitis occurred in 2.4% (31/1281) of patients receiving LIBTAYO, including fatal (< 0.1%), Grade 4 (0.3%), Grade 3 (1.6%), and Grade 2 (0.2%) adverse reactions. Hepatitis led to permanent discontinuation of LIBTAYO in 1.4% of patients and withholding of LIBTAYO in 0.7% of patients. Systemic corticosteroids were required in all patients with hepatitis. Thirteen percent (13%) of these patients (4/31) required additional immunosuppression with mycophenolate. Hepatitis resolved in 39% of the 31 patients. Of the 9 patients in whom LIBTAYO was withheld for hepatitis, 5 patients reinitiated LIBTAYO after symptom improvement; of these, 1/5 (20%) had recurrence of hepatitis. Immune-Mediated Endocrinopathies Adrenal Insufficiency LIBTAYO can cause primary or secondary adrenal insufficiency. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold LIBTAYO depending on severity [see Dosage and Administration (2.3) ] . Adrenal insufficiency occurred in 0.5% (6/1281) of patients receiving LIBTAYO, including Grade 3 (0.5%) adverse reactions. Adrenal insufficiency led to permanent discontinuation of LIBTAYO in 1 (< 0.1%) patient. LIBTAYO was withheld in 1 (< 0.1%) patient due to adrenal insufficiency and not reinitiated. Systemic corticosteroids were required in 83% (5/6) patients with adrenal insufficiency; of these, the majority remained on systemic corticosteroids. Adrenal insufficiency resolved in 17% of the 6 patients. Hypophysitis LIBTAYO can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as clinically indicated. Withhold or permanently discontinue LIBTAYO depending on severity [see Dosage and Administration (2.3) ]. Hypophysitis occurred in 0.5% (7/1281) of patients receiving LIBTAYO, including Grade 3 (0.2%) and Grade 2 (0.3%) adverse reactions. Hypophysitis led to permanent discontinuation of LIBTAYO in 1 (< 0.1%) patient and withholding of LIBTAYO in 2 (0.2%) patients. Systemic corticosteroids were required in 86% (6/7) patients with hypophysitis. Hypophysitis resolved in 14% of the 7 patients. Of the 2 patients in whom LIBTAYO was withheld for hypophysitis, none of the patients reinitiated. Thyroid Disorders LIBTAYO can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement or medical management as clinically indicated. Withhold or permanently discontinue LIBTAYO depending on severity [see Dosage and Administration (2.3) ] . Thyroiditis: Thyroiditis occurred in 0.6% (8/1281) of patients receiving LIBTAYO, including Grade 2 (0.3%) adverse reactions. No patient discontinued LIBTAYO due to thyroiditis. Thyroiditis led to withholding of LIBTAYO in 1 (< 0.1%) patient. Systemic corticosteroids were not required in any patient with thyroiditis. Thyroiditis resolved in 13% of the 8 patients. Blood thyroid stimulating hormone increased and blood thyroid stimulating hormone decreased have also been reported. Hyperthyroidism: Hyperthyroidism occurred in 3% (39/1281) of patients receiving LIBTAYO, including Grade 3 (< 0.1%) and Grade 2 (0.9%) adverse reactions. No patient discontinued treatment due to hyperthyroidism. Hyperthyroidism led to withholding of LIBTAYO in 7 (0.5%) patients. Systemic corticosteroids were required in 8% (3/39) of patients with hyperthyroidism. Hyperthyroidism resolved in 56% of the 39 patients. Of the 7 patients in whom LIBTAYO was withheld for hyperthyroidism, 2 patients reinitiated LIBTAYO after symptom improvement; of these, none had recurrence of hyperthyroidism. Hypothyroidism: Hypothyroidism occurred in 7% (87/1281) of patients receiving LIBTAYO, including Grade 3 (< 0.1%) and Grade 2 (6%) adverse reactions . Hypothyroidism led to permanent discontinuation of LIBTAYO in 3 (0.2%) patients. Hypothyroidism led to withholding of LIBTAYO in 9 (0.7%) patients. Systemic corticosteroids were required in 1.1% (1/87) of patients. Hypothyroidism resolved in 6% of the 87 patients. The majority of patients with hypothyroidism required long-term thyroid hormone replacement. Of the 9 patients in whom LIBTAYO was withheld for hypothyroidism, 1 reinitiated LIBTAYO after symptom improvement and did not have recurrence of hypothyroidism. Type 1 Diabetes Mellitus, which can present with diabetic ketoacidosis Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold LIBTAYO depending on severity [see Dosage and Administration (2.3) ] . Type 1 diabetes mellitus occurred in < 0.1% (1/1281) of patients (Grade 4). No patient discontinued treatment due to type 1 diabetes mellitus. Type 1 diabetes mellitus led to withholding of LIBTAYO in 0.1% of patients, treatment was reinitiated after symptom improvement. Patient received long-term insulin therapy. Immune-Mediated Nephritis with Renal Dysfunction LIBTAYO can cause immune-mediated nephritis. The definition of immune-mediated nephritis included the required use of systemic corticosteroids or other immunosuppressants and the absence of a clear alternate etiology. Immune-mediated nephritis occurred in 0.7% (9/1281) patients receiving LIBTAYO, including fatal (< 0.1%), Grade 3 (< 0.1%) and Grade 2 (0.5%) adverse reactions. Nephritis led to permanent discontinuation of LIBTAYO in 0.2% of patients and withholding of LIBTAYO in 0.4% of patients. Systemic corticosteroids were required in all patients with nephritis. Nephritis resolved in 78% of the 9 patients. Of the 5 patients in whom LIBTAYO was withheld for nephritis, 4 reinitiated LIBTAYO after symptom improvement; of these, 1/4 (25%) had recurrence of nephritis. Immune-Mediated Dermatologic Adverse Reactions LIBTAYO can cause immune-mediated rash or dermatitis. The definition of immune-mediated dermatologic adverse reaction included the required use of systemic corticosteroids or other immunosuppressants and the absence of a clear alternate etiology. Exfoliative dermatitis, including Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and DRESS (Drug Rash with Eosinophilia and Systemic Symptoms), has occurred with PD-1/PD-L1 blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-exfoliative rashes. Withhold or permanently discontinue LIBTAYO depending on severity [see Dosage and Administration (2.3) ] . Immune-mediated dermatologic adverse reactions occurred in 1.9% (24/1281) of patients receiving LIBTAYO, including Grade 3 (0.9%) and Grade 2 (0.8%) adverse reactions. Dermatologic adverse reactions led to permanent discontinuation of LIBTAYO in 0.2% of patients and withholding of LIBTAYO in 1.3% of patients. Systemic corticosteroids were required in all patients with immune-mediated dermatologic adverse reactions. Immune-mediated dermatologic adverse reactions resolved in 71% of the 24 patients. Of the 17 patients in whom LIBTAYO was withheld for dermatologic adverse reaction, 13 reinitiated LIBTAYO after symptom improvement; of these 5/13 (38%) had recurrence of the dermatologic adverse reaction. Other Immune-Mediated Adverse Reactions The following clinically significant immune-mediated adverse reactions occurred at an incidence of <1% in 1281 patients who received LIBTAYO or were reported with the use of other PD-1/PD-L1 blocking antibodies . Severe or fatal cases have been reported for some of these adverse reactions. Cardiac/Vascular: Myocarditis, pericarditis, vasculitis Nervous System: Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barre syndrome, nerve paresis, autoimmune neuropathy Ocular: Uveitis, iritis, and other ocular inflammatory toxicities. Some cases can be associated with retinal detachment. Various grades of visual impairment to include blindness can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss Gastrointestinal: Pancreatitis to include increases in serum amylase and lipase levels, gastritis, duodenitis, stomatitis Musculoskeletal and Connective Tissue: Myositis/polymyositis/dermatomyositis, rhabdomyolysis and associated sequelae including renal failure, arthritis, polymyalgia rheumatica Endocrine: Hypoparathyroidism Other (Hematologic/Immune): Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenia, solid organ transplant rejection, other transplant (including corneal graft) rejection 5.2 Infusion-Related Reactions Severe or life-threatening infusion-related reactions occurred in 0.2% of patients receiving LIBTAYO as a single agent. Monitor patients for signs and symptoms of infusion-related reactions. Common symptoms of infusion-related reaction include nausea, pyrexia, and vomiting. Interrupt or slow the rate of infusion or permanently discontinue LIBTAYO based on severity of reaction [see Dosage and Administration (2.3) ] . 5.3 Complications of Allogeneic HSCT Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/PD-L1 blocking antibody. Transplant-related complications include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT. Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1/PD-L1 blocking antibody prior to or after an allogeneic HSCT. 5.4 Embryo-Fetal Toxicity Based on its mechanism of action, LIBTAYO can cause fetal harm when administered to a pregnant woman. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death. Advise women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with LIBTAYO and for at least 4 months after the last dose [see Use in Specific Populations (8.1 , 8.3) ] ."],"clinical_studies_table":["<table width=\"85%\"><caption>Table 13: Efficacy Results for Study 1540 in Advanced CSCC</caption><col width=\"38%\" align=\"left\" valign=\"top\"/><col width=\"16%\" align=\"center\" valign=\"top\"/><col width=\"15%\" align=\"center\" valign=\"top\"/><col width=\"15%\" align=\"center\" valign=\"top\"/><col width=\"16%\" align=\"center\" valign=\"top\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\">Efficacy Endpoints<footnote>Median duration of follow up: mCSCC 3 mg/kg every 2 weeks: 18.5 months; laCSCC 3 mg/kg every 2 weeks: 15.5 months; mCSCC 350 mg every 3 weeks: 17.3 months; combined CSCC: 15.7 months</footnote></th><th styleCode=\"Rrule\">Metastatic CSCC LIBTAYO 3 mg/kg every 2 weeks   (Group 1)</th><th styleCode=\"Rrule\">Locally Advanced CSCC LIBTAYO 3 mg/kg every 2 weeks   (Group 2)</th><th styleCode=\"Rrule\">Metastatic CSCC LIBTAYO 350 mg every 3 weeks   (Group 3)</th><th styleCode=\"Rrule\">Combined CSCC</th></tr><tr><th styleCode=\"Lrule Rrule\"/><th styleCode=\"Rrule\">N = 59</th><th styleCode=\"Rrule\">N = 78</th><th styleCode=\"Rrule\">N = 56</th><th styleCode=\"Rrule\">N = 193</th></tr></thead><tfoot><tr><td colspan=\"5\" align=\"left\">CI: confidence interval; NR: not reached</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">Confirmed Objective Response Rate (ORR) (%)</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> ORR (95% CI)</td><td styleCode=\"Rrule\">51 (37, 64)</td><td styleCode=\"Rrule\">45 (34, 57)</td><td styleCode=\"Rrule\">46 (33, 60)</td><td styleCode=\"Rrule\">47 (40, 54)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Complete response rate<footnote>Only includes patients with complete healing of prior cutaneous involvement; laCSCC patients in Study 1540 required biopsy to confirm CR</footnote></td><td styleCode=\"Rrule\">20</td><td styleCode=\"Rrule\">13</td><td styleCode=\"Rrule\">20</td><td styleCode=\"Rrule\">17</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Partial response rate</td><td styleCode=\"Rrule\">31</td><td styleCode=\"Rrule\">32</td><td styleCode=\"Rrule\">27</td><td styleCode=\"Rrule\">30</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">Duration of Response (DOR)</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Number of Responders</td><td styleCode=\"Rrule\">N = 30</td><td styleCode=\"Rrule\">N = 35</td><td styleCode=\"Rrule\">N = 26</td><td styleCode=\"Rrule\">N = 91</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Median DOR in months<footnote>Based on Kaplan-Meier estimate</footnote> (Range)</td><td styleCode=\"Rrule\">NR (2.8 &#x2013; 38.9)</td><td styleCode=\"Rrule\">42 (1.9 &#x2013; 54.6)</td><td styleCode=\"Rrule\">41 (4.2 &#x2013; 46.3)</td><td styleCode=\"Rrule\">41 (1.9 &#x2013; 54.6)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Patients with observed DOR &#x2265;6 months, n (%)<footnote ID=\"t13f1\">The numerator includes the number of patients whose observed DOR reached at least the specified times of 6 or 12 months. Patients who did not have the opportunity to reach the specified timepoint were included in the denominator only</footnote></td><td styleCode=\"Rrule\">28 (93%)</td><td styleCode=\"Rrule\">31 (89%)</td><td styleCode=\"Rrule\">25 (96%)</td><td styleCode=\"Rrule\">84 (92%)</td></tr><tr><td styleCode=\"Lrule Rrule\"> Patients with observed DOR &#x2265;12 months, n (%)<footnoteRef IDREF=\"t13f1\"/></td><td styleCode=\"Rrule\">23 (77%)</td><td styleCode=\"Rrule\">24 (69%)</td><td styleCode=\"Rrule\">23 (88%)</td><td styleCode=\"Rrule\">70 (77%)</td></tr></tbody></table>","<table width=\"85%\"><caption>Table 14: Efficacy Results for the C-POST Study in Patients with CSCC at High Risk of Recurrence in the Adjuvant Setting</caption><col width=\"40%\" align=\"left\" valign=\"top\"/><col width=\"30%\" align=\"center\" valign=\"top\"/><col width=\"30%\" align=\"center\" valign=\"top\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" rowspan=\"2\">Efficacy Endpoints</th><th styleCode=\"Rrule\">LIBTAYO</th><th styleCode=\"Rrule\">Placebo</th></tr><tr><th styleCode=\"Lrule Rrule\" align=\"center\">N = 209</th><th styleCode=\"Rrule\">N = 206</th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"3\">CI: confidence interval; NE: not evaluable; NR: not reached</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Disease-Free Survival (DFS)</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Number of events, n (%)</td><td styleCode=\"Rrule\">24 (12%)</td><td styleCode=\"Rrule\">65 (32%)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Disease recurrences, n (%) <list listType=\"unordered\" styleCode=\"disc\"><item>Distant recurrence, n (%)</item><item>Locoregional recurrence, n (%)</item></list></td><td styleCode=\"Rrule\">18 (9%)   10 (4.8%)   8 (3.8%)</td><td styleCode=\"Rrule\">61 (30%)   26 (13%)   35 (17%)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Deaths, n (%)</td><td styleCode=\"Rrule\">6 (2.9%)</td><td styleCode=\"Rrule\">4 (1.9%)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Median (95% CI) in months<footnote>Based on Kaplan-Meier method</footnote></td><td styleCode=\"Rrule\">NR (NE, NE)</td><td styleCode=\"Rrule\">49.4 (48.5, NE)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Hazard ratio (95% CI)<footnote>Based on stratified proportional hazards model</footnote></td><td styleCode=\"Rrule\" colspan=\"2\">0.32 (0.20, 0.51)</td></tr><tr><td styleCode=\"Lrule Rrule\"> p-value<footnote>Based on a two-sided stratified log-rank test</footnote></td><td styleCode=\"Rrule\" colspan=\"2\">&lt;0.0001</td></tr></tbody></table>","<table width=\"80%\"><caption>Table 15: Efficacy Results for Study 1620 in BCC</caption><col width=\"40%\" align=\"left\" valign=\"middle\"/><col width=\"28%\" align=\"center\" valign=\"middle\"/><col width=\"32%\" align=\"center\" valign=\"middle\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\">Efficacy Endpoints<footnote>Median duration of follow up: mBCC 8.4 months; laBCC 15.9 months</footnote></th><th styleCode=\"Rrule\">Metastatic BCC</th><th styleCode=\"Rrule\">Locally Advanced BCC</th></tr><tr><th styleCode=\"Lrule Rrule\"/><th styleCode=\"Rrule\">N = 54</th><th styleCode=\"Rrule\">N = 84</th></tr></thead><tfoot><tr><td colspan=\"3\" align=\"left\">CI: confidence interval; NR: not reached; +: denotes ongoing at last assessment</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Confirmed Objective Response Rate (ORR) (%)</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> ORR (95% CI)</td><td styleCode=\"Rrule\">22 (12, 36)</td><td styleCode=\"Rrule\">32 (22, 43)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Complete response rate</td><td styleCode=\"Rrule\">1.9</td><td styleCode=\"Rrule\">7</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Partial response rate</td><td styleCode=\"Rrule\">20</td><td styleCode=\"Rrule\">25</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Duration of Response</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Number of Responders</td><td styleCode=\"Rrule\">N = 12</td><td styleCode=\"Rrule\">N = 27</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Median DOR in months<footnote>Based on Kaplan-Meier estimate</footnote> (Range)</td><td styleCode=\"Rrule\">16.7 (9.0 &#x2013; 25.8+)</td><td styleCode=\"Rrule\">NR (2.1 &#x2013; 36.8+)</td></tr><tr><td styleCode=\"Lrule Rrule\"> Patients with observed DOR &#x2265;6 months, n (%)</td><td styleCode=\"Rrule\" valign=\"top\">12 (100%)</td><td styleCode=\"Rrule\" valign=\"top\">23 (85%)</td></tr></tbody></table>","<table width=\"80%\"><caption>Table 16: Efficacy Results from Study 16113 in Non-Small Cell Lung Cancer</caption><col width=\"40%\" align=\"left\" valign=\"middle\"/><col width=\"30%\" align=\"center\" valign=\"middle\"/><col width=\"30%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\">Endpoints</th><th styleCode=\"Rrule\">LIBTAYO and Chemotherapy   N=312</th><th styleCode=\"Rrule\">Placebo and Chemotherapy   N=154</th></tr></thead><tfoot><tr><td colspan=\"3\" align=\"left\">BICR: blinded independent central review; CI: confidence interval; NE: not evaluable; +: ongoing response</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Overall Survival</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Deaths, n (%)</td><td styleCode=\"Rrule\">132 (42)</td><td styleCode=\"Rrule\">82 (53)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Median in months (95% CI)<footnote ID=\"t16f1\">Based on Kaplan-Meier method</footnote></td><td styleCode=\"Rrule\">21.9 (15.5, NE)</td><td styleCode=\"Rrule\">13.0 (11.9, 16.1)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Hazard ratio (95% CI)<footnote ID=\"t16f2\">Based on stratified proportional hazards model</footnote></td><td styleCode=\"Rrule\" colspan=\"2\">0.71 (0.53, 0.93)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">p-value<footnote ID=\"t16f3\">Based on a two-sided p-value</footnote></td><td styleCode=\"Rrule\" colspan=\"2\">0.0140</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Progression-free Survival per BICR</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Events, n (%)</td><td styleCode=\"Rrule\">204 (65)</td><td styleCode=\"Rrule\">122 (79)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Median in months (95% CI)<footnoteRef IDREF=\"t16f1\"/></td><td styleCode=\"Rrule\">8.2 (6.4, 9.3)</td><td styleCode=\"Rrule\">5.0 (4.3, 6.2)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Hazard ratio (95% CI)<footnoteRef IDREF=\"t16f2\"/></td><td styleCode=\"Rrule\" colspan=\"2\">0.56 (0.44, 0.70)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">p-value<footnoteRef IDREF=\"t16f3\"/></td><td styleCode=\"Rrule\" colspan=\"2\">&lt;0.0001</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Overall Response Rate per BICR (%)</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">ORR (95% CI)<footnote>Clopper-Pearson exact confidence interval</footnote></td><td styleCode=\"Rrule\">43 (38, 49)</td><td styleCode=\"Rrule\">23 (16, 30)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Complete response (CR) rate</td><td styleCode=\"Rrule\">2.6</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Partial response (PR) rate</td><td styleCode=\"Rrule\">41</td><td styleCode=\"Rrule\">23</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> p-value<footnoteRef IDREF=\"t16f3\"/></td><td styleCode=\"Rrule\" colspan=\"2\">&lt;0.0001</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Duration of Response per BICR</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr><td styleCode=\"Lrule Rrule\">Median in months<footnoteRef IDREF=\"t16f1\"/> (range)</td><td styleCode=\"Rrule\">15.6 (1.7, 18.7+)</td><td styleCode=\"Rrule\">7.3 (1.8, 18.8+)</td></tr></tbody></table>","<table width=\"80%\"><caption>Table 17: Efficacy Results from Study 1624 in Non-Small Cell Lung Cancer</caption><col width=\"40%\" align=\"left\" valign=\"top\"/><col width=\"30%\" align=\"center\" valign=\"top\"/><col width=\"30%\" align=\"center\" valign=\"top\"/><thead><tr><th styleCode=\"Lrule Rrule\">Endpoints</th><th styleCode=\"Rrule\">LIBTAYO   N=356</th><th styleCode=\"Rrule\">Chemotherapy   N=354</th></tr></thead><tfoot><tr><td colspan=\"3\" align=\"left\">BICR: blinded independent central review; CI: confidence interval; NE: not evaluable; +: ongoing response</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Overall Survival</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Number of deaths (%)</td><td styleCode=\"Rrule\">108 (30)</td><td styleCode=\"Rrule\">141 (40)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Median in months (95% CI)<footnote ID=\"t17f1\">Based on Kaplan-Meier method</footnote></td><td styleCode=\"Rrule\">22.1 (17.7, NE)</td><td styleCode=\"Rrule\">14.3 (11.7, 19.2)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Hazard ratio (95% CI)<footnote ID=\"t17f2\">Based on stratified proportional hazards model</footnote></td><td styleCode=\"Rrule\" colspan=\"2\">0.68 (0.53, 0.87)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">p-value</td><td styleCode=\"Rrule\" colspan=\"2\">0.0022</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Progression-free Survival per BICR</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Number of events (%)</td><td styleCode=\"Rrule\">201 (57)</td><td styleCode=\"Rrule\">262 (74)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Median in months (95% CI)<footnoteRef IDREF=\"t17f1\"/></td><td styleCode=\"Rrule\">6.2 (4.5, 8.3)</td><td styleCode=\"Rrule\">5.6 (4.5, 6.1)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Hazard ratio (95% CI)<footnoteRef IDREF=\"t17f2\"/></td><td styleCode=\"Rrule\" colspan=\"2\">0.59 (0.49, 0.72)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">p-value</td><td styleCode=\"Rrule\" colspan=\"2\">&lt;0.0001</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Overall Response Rate per BICR (%)<footnote>Clopper-Pearson exact confidence interval</footnote></content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">ORR (95% CI)</td><td styleCode=\"Rrule\">37 (32, 42)</td><td styleCode=\"Rrule\">21 (17, 25)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Complete response (CR) rate</td><td styleCode=\"Rrule\">3</td><td styleCode=\"Rrule\">1</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Partial response (PR) rate</td><td styleCode=\"Rrule\">33</td><td styleCode=\"Rrule\">20</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Duration of Response per BICR</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr><td styleCode=\"Lrule Rrule\">Median in months (range)</td><td styleCode=\"Rrule\">21.0 (1.9+, 23.3+)</td><td styleCode=\"Rrule\">6.0 (1.3+, 16.5+)</td></tr></tbody></table>"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No studies have been performed to assess the potential of cemiplimab-rwlc for carcinogenicity or genotoxicity. In a 3-month repeat-dose toxicology study in sexually mature cynomolgus monkeys, there were no cemiplimab-rwlc-related effects on fertility parameters (menstrual cycle, semen analysis, or testicular measurements) or in male or female reproductive organs at doses up to the highest dose tested, 50 mg/kg/week (approximately 5.5 to 25.5 times the human exposure based on AUC at the clinical dose of 350 mg once every 3 weeks). 13.2 Animal Toxicology and/or Pharmacology In animal models, inhibition of PD-L1/PD-1 signaling increased the severity of some infections and enhanced inflammatory responses. M. tuberculosis –infected PD-1 knockout mice exhibit markedly decreased survival compared with wild-type controls, which correlated with increased bacterial proliferation and inflammatory responses in these animals. PD-L1 and PD-1 knockout mice and mice receiving PD-L1 blocking antibody have also shown decreased survival following infection with lymphocytic choriomeningitis virus."],"adverse_reactions_table":["<table width=\"80%\"><caption>Table 3: Adverse Reactions in &#x2265;10% of Patients with Advanced CSCC Receiving LIBTAYO in Study 1540</caption><col width=\"50%\" align=\"left\" valign=\"top\"/><col width=\"25%\" align=\"center\" valign=\"top\"/><col width=\"25%\" align=\"center\" valign=\"top\"/><thead><tr><th styleCode=\"Lrule Rrule\" rowspan=\"2\" valign=\"middle\">Adverse Reactions</th><th styleCode=\"Rrule Botrule\" colspan=\"2\">LIBTAYO   N = 358</th></tr><tr><th styleCode=\"Rrule\" align=\"center\">All Grades   %</th><th styleCode=\"Rrule\">Grades 3-4   %</th></tr></thead><tfoot><tr><td colspan=\"3\" align=\"left\">Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v.4.03</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">General and Administration Site</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Fatigue<footnote>Fatigue is a composite term that includes fatigue and asthenia</footnote></td><td styleCode=\"Rrule\">38</td><td styleCode=\"Rrule\">2.2</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Skin and Subcutaneous Tissue</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Rash<footnote>Rash is a composite term that includes rash, rash maculo-papular, dermatitis, erythema, eczema, dermatitis bullous, rash erythematous, dermatitis acneiform, psoriasis, dermatitis contact, blister, pemphigoid, rash papular, hand dermatitis, skin exfoliation, autoimmune dermatitis, rash pruritic, rash macular, rash pustular, urticaria, dermatitis atopic, drug eruption, eczema asteatotic, skin reaction, dermatitis psoriasiform, eczema nummular, exfoliative rash, and immune-mediated dermatitis</footnote></td><td styleCode=\"Rrule\">34</td><td styleCode=\"Rrule\">1.7</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Pruritus<footnote>Pruritus is a composite term that includes pruritus and pruritus allergic</footnote></td><td styleCode=\"Rrule\">22</td><td styleCode=\"Rrule\">0.3</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Actinic keratosis</td><td styleCode=\"Rrule\">10</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Musculoskeletal and Connective Tissue</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Musculoskeletal pain<footnote>Musculoskeletal pain is a composite term that includes arthralgia, back pain, myalgia, polyarthritis, pain in extremity, neck pain, non-cardiac chest pain, arthritis, musculoskeletal chest pain, musculoskeletal pain, musculoskeletal stiffness, bone pain, immune-mediated arthritis, and spinal pain</footnote></td><td styleCode=\"Rrule\">33</td><td styleCode=\"Rrule\">2.5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Gastrointestinal</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Diarrhea<footnote>Diarrhea is a composite term that includes diarrhea, colitis, and autoimmune colitis</footnote></td><td styleCode=\"Rrule\">26</td><td styleCode=\"Rrule\">1.1</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Nausea</td><td styleCode=\"Rrule\">21</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Constipation</td><td styleCode=\"Rrule\">13</td><td styleCode=\"Rrule\">0.3</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Vomiting<footnote>Vomiting is a composite term that includes hematemesis and vomiting</footnote></td><td styleCode=\"Rrule\">11</td><td styleCode=\"Rrule\">0.6</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Infections and infestations</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Upper respiratory tract infection<footnote>Upper respiratory tract infection is a composite term that includes upper respiratory tract infection, nasopharyngitis, sinusitis, influenza-like illness, rhinitis, influenza, viral upper respiratory tract infection, respiratory tract infection, influenza A virus test positive, and pharyngitis</footnote></td><td styleCode=\"Rrule\">14</td><td styleCode=\"Rrule\">1.1</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Skin infection<footnote>Skin infection is a composite term that includes skin infection, cellulitis, fungal skin infection, and staphylococcal skin infection</footnote></td><td styleCode=\"Rrule\">11</td><td styleCode=\"Rrule\">4.5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Respiratory</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Cough<footnote>Cough is a composite term that includes cough, productive cough, and upper airway cough syndrome</footnote></td><td styleCode=\"Rrule\">12</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Metabolism and Nutrition</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Decreased appetite</td><td styleCode=\"Rrule\">11</td><td styleCode=\"Rrule\">0.6</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Nervous system disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Headache<footnote>Headache is a composite term that includes headache, sinus headache, and migraine</footnote></td><td styleCode=\"Rrule\">10</td><td styleCode=\"Rrule\">0</td></tr><tr><td styleCode=\"Lrule Rrule\"> Dizziness<footnote>Dizziness is a composite term that includes dizziness, vertigo, vertigo positional, and dizziness postural</footnote></td><td styleCode=\"Rrule\">10</td><td styleCode=\"Rrule\">0.3</td></tr></tbody></table>","<table width=\"80%\"><caption>Table 4: Grade 3 or 4 Laboratory Abnormalities Worsening from Baseline in &#x2265;1% of Patients with Advanced CSCC Receiving LIBTAYO in Study 1540</caption><col width=\"50%\" align=\"left\" valign=\"middle\"/><col width=\"50%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\">Laboratory Abnormality</th><th styleCode=\"Rrule\">Grade 3-4 (%)<footnote>Percentages are based on the number of patients with at least 1 post-baseline value available for that parameter</footnote></th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"2\">Toxicity graded per NCI CTCAE v. 4.03</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\"><content styleCode=\"bold\">Hematology</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Lymphopenia</td><td styleCode=\"Rrule\">7.0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Anemia</td><td styleCode=\"Rrule\">4.1</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\"><content styleCode=\"bold\">Electrolytes</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Hyponatremia</td><td styleCode=\"Rrule\">4.9</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Hypophosphatemia</td><td styleCode=\"Rrule\">4.1</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Hypercalcemia</td><td styleCode=\"Rrule\">2.0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Hypokalemia</td><td styleCode=\"Rrule\">1.5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\"><content styleCode=\"bold\">Coagulation</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Increased INR</td><td styleCode=\"Rrule\">2.9</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\"><content styleCode=\"bold\">Chemistry</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Increased aspartate aminotransferase</td><td styleCode=\"Rrule\">1.5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Hypoalbuminemia</td><td styleCode=\"Rrule\">1.2</td></tr></tbody></table>","<table width=\"80%\"><caption>Table 5: Adverse Reactions in &#x2265;10% of Patients with CSCC at High Risk of Recurrence in the Adjuvant Setting Receiving LIBTAYO with a Difference Between Arms of &#x2265;3% Compared to Placebo in C-POST study</caption><col width=\"36%\" align=\"left\" valign=\"top\"/><col width=\"16%\" align=\"center\" valign=\"top\"/><col width=\"16%\" align=\"center\" valign=\"top\"/><col width=\"16%\" align=\"center\" valign=\"top\"/><col width=\"16%\" align=\"center\" valign=\"top\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" rowspan=\"2\" valign=\"middle\">Adverse reactions<footnote>Toxicity graded per NCI CTCAE v. 5.</footnote></th><th styleCode=\"Rrule\" colspan=\"2\">LIBTAYO   N=205</th><th styleCode=\"Rrule\" colspan=\"2\">Placebo   N=204</th></tr><tr><th styleCode=\"Rrule\" align=\"center\">All Grades   %</th><th styleCode=\"Rrule\">Grades 3-4   %</th><th styleCode=\"Rrule\">All Grades   %</th><th styleCode=\"Rrule\">Grades 3-4   %</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Skin and subcutaneous tissue disorders</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Rash<footnote>Includes multiple related terms</footnote></td><td styleCode=\"Rrule\">37</td><td styleCode=\"Rrule\">2</td><td styleCode=\"Rrule\">21</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Pruritus</td><td styleCode=\"Rrule\">16</td><td styleCode=\"Rrule\">0.5</td><td styleCode=\"Rrule\">12</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Endocrine disorders</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr><td styleCode=\"Lrule Rrule\"> Hypothyroidism</td><td styleCode=\"Rrule\">12</td><td styleCode=\"Rrule\">0.5</td><td styleCode=\"Rrule\">2.9</td><td styleCode=\"Rrule\">0</td></tr></tbody></table>","<table width=\"80%\"><caption>Table 6: Laboratory Abnormalities Worsening from Baseline in &#x2265;1% of Patients with CSCC at High Risk of Recurrence in the Adjuvant Setting Receiving LIBTAYO in C-POST Study</caption><col width=\"40%\" align=\"left\" valign=\"middle\"/><col width=\"20%\" align=\"center\" valign=\"middle\"/><col width=\"40%\" align=\"center\" valign=\"middle\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" rowspan=\"2\">Laboratory Abnormality</th><th styleCode=\"Rrule\">LIBTAYO</th><th styleCode=\"Rrule\">Placebo</th></tr><tr><th styleCode=\"Rrule\" colspan=\"2\" align=\"center\">Grade 3-4 (%)<footnote>The denominator used to calculate the rate varied from 201 to 203 based on the number of patients with a baseline value and at least one post-treatment value.</footnote></th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"3\">Toxicity graded per NCI CTCAE v. 5</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Hematology</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Lymphocyte count decreased</td><td styleCode=\"Rrule\">6</td><td styleCode=\"Rrule\">3</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Chemistry</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Alanine aminotransferase increased</td><td styleCode=\"Rrule\">3.9</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Aspartate aminotransferase increased</td><td styleCode=\"Rrule\">3</td><td styleCode=\"Rrule\">0.5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Alkaline phosphatase increased</td><td styleCode=\"Rrule\">1.5</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Albumin decreased</td><td styleCode=\"Rrule\">1</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Electrolytes</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Calcium decreased</td><td styleCode=\"Rrule\">1</td><td styleCode=\"Rrule\">1</td></tr><tr><td styleCode=\"Lrule Rrule\"> Potassium decreased</td><td styleCode=\"Rrule\">1</td><td styleCode=\"Rrule\">0.5</td></tr></tbody></table>","<table width=\"80%\"><caption>Table 7: Adverse Reactions in &#x2265;10% of Patients with Advanced BCC Receiving LIBTAYO in Study 1620</caption><col width=\"45%\" align=\"left\" valign=\"middle\"/><col width=\"30%\" align=\"center\" valign=\"middle\"/><col width=\"25%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\" rowspan=\"2\">Adverse Reactions</th><th styleCode=\"Rrule Botrule\" colspan=\"2\">LIBTAYO   N = 138</th></tr><tr><th styleCode=\"Rrule\" align=\"center\">All Grades   %</th><th styleCode=\"Rrule\">Grades 3-4   %</th></tr></thead><tfoot><tr><td colspan=\"3\" align=\"left\">Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v.4.03</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">General disorders and administration site conditions</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Fatigue<footnote>Fatigue is a composite term that includes fatigue, asthenia, and malaise</footnote></td><td styleCode=\"Rrule\">50</td><td styleCode=\"Rrule\">4.3</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Edema<footnote>Edema is a composite term that includes peripheral edema, peripheral swelling, and face swelling</footnote></td><td styleCode=\"Rrule\">10</td><td styleCode=\"Rrule\">0.7</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Musculoskeletal and connective tissue disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Musculoskeletal pain<footnote>Musculoskeletal pain is a composite term that includes arthralgia, back pain, pain in extremity, myalgia, neck pain, non-cardiac chest pain, arthritis, musculoskeletal chest pain, musculoskeletal stiffness, musculoskeletal discomfort, and spinal pain</footnote></td><td styleCode=\"Rrule\">36</td><td styleCode=\"Rrule\">2.9</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Gastrointestinal disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Diarrhea<footnote>Diarrhea is a composite term that includes diarrhea, colitis, autoimmune colitis, and enterocolitis </footnote></td><td styleCode=\"Rrule\">33</td><td styleCode=\"Rrule\">4.3</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Nausea</td><td styleCode=\"Rrule\">13</td><td styleCode=\"Rrule\">0.7</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Abdominal pain<footnote>Abdominal pain is a composite term that includes abdominal pain, abdominal pain upper, abdominal pain lower, and gastrointestinal pain</footnote></td><td styleCode=\"Rrule\">12</td><td styleCode=\"Rrule\">1.4</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Constipation</td><td styleCode=\"Rrule\">12</td><td styleCode=\"Rrule\">0.7</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Skin and subcutaneous tissue disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Rash<footnote>Rash is a composite term that includes rash maculo-papular, eczema, rash, dermatitis, erythema, dermatitis acneiform, rash pruritic, rash pustular, dermatitis bullous, dyshidrotic eczema, pemphigoid, rash erythematous, urticaria, nodular rash, and skin exfoliation</footnote></td><td styleCode=\"Rrule\">30</td><td styleCode=\"Rrule\">0.7</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Pruritus</td><td styleCode=\"Rrule\">19</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Infections and infestations</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Upper respiratory tract infection<footnote>Upper respiratory tract infection is a composite term that includes upper respiratory tract infection, influenza-like illness, nasopharyngitis, rhinitis, sinusitis, viral rhinitis, pharyngitis, laryngitis, respiratory tract infection, influenza, viral upper respiratory tract infection, and influenza A virus test positive</footnote></td><td styleCode=\"Rrule\">22</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Urinary tract infection<footnote>Urinary tract infection is a composite term that includes urinary tract infection, cystitis, and urosepsis</footnote></td><td styleCode=\"Rrule\">13</td><td styleCode=\"Rrule\">2.2</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Vascular disorders</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Hemorrhage<footnote>Hemorrhage is a composite term that includes tumor hemorrhage, hematuria, epistaxis, eye hemorrhage, hemoptysis, hemorrhage intracranial, hemorrhagic diathesis, postmenopausal hemorrhage, rectal hemorrhage, skin hemorrhage, skin neoplasm bleeding, ulcer hemorrhage, vaginal hemorrhage, wound hemorrhage, and subcutaneous hematoma</footnote></td><td styleCode=\"Rrule\">18</td><td styleCode=\"Rrule\">0.7</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Hypertension<footnote>Hypertension is a composite term that includes hypertension, blood pressure increased, and hypertensive crisis</footnote></td><td styleCode=\"Rrule\">17</td><td styleCode=\"Rrule\">9</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Metabolism and nutrition disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Decreased appetite</td><td styleCode=\"Rrule\">14</td><td styleCode=\"Rrule\">1.4</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Blood and lymphatic system disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Anemia</td><td styleCode=\"Rrule\">14</td><td styleCode=\"Rrule\">0.7</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Respiratory, thoracic, and mediastinal disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Dyspnea<footnote>Dyspnea is a composite term that includes dyspnea and dyspnea exertional</footnote></td><td styleCode=\"Rrule\">14</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Renal and urinary disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Acute kidney injury<footnote>Acute kidney injury is a composite term that includes blood creatinine increased, acute kidney injury, renal failure, renal impairment, glomerular filtration rate decreased, and nephropathy toxic</footnote></td><td styleCode=\"Rrule\">14</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Nervous system disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Headache</td><td styleCode=\"Rrule\">13</td><td styleCode=\"Rrule\">1.4</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Dizziness<footnote>Dizziness is a composite term that includes dizziness and vertigo</footnote></td><td styleCode=\"Rrule\">12</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Peripheral neuropathy<footnote>Peripheral neuropathy is a composite term that includes paresthesia, dysesthesia, hypoesthesia, peripheral motor neuropathy, burning sensation, neuralgia, and peripheral sensory neuropathy</footnote></td><td styleCode=\"Rrule\">11</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Endocrine disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Hypothyroidism<footnote>Hypothyroidism is a composite term that includes hypothyroidism, blood thyroid stimulating hormone increased, and immune-mediated hypothyroidism</footnote></td><td styleCode=\"Rrule\">12</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Investigations</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr><td styleCode=\"Lrule Rrule\">Liver function test abnormalities<footnote>Liver function test abnormalities is a composite term that includes alanine aminotransferase increased, aspartate aminotransferase increased, bilirubin conjugated increased, blood alkaline phosphatase increased, blood bilirubin increased, and gamma-glutamyl transferase increased</footnote></td><td styleCode=\"Rrule\">10</td><td styleCode=\"Rrule\">1.4</td></tr></tbody></table>","<table width=\"80%\"><caption>Table 8: Grade 3 or 4 Laboratory Abnormalities Worsening from Baseline in &#x2265;1% of Patients with Advanced BCC Receiving LIBTAYO in Study 1620</caption><col width=\"50%\" align=\"left\" valign=\"middle\"/><col width=\"50%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\">Laboratory Abnormality</th><th styleCode=\"Rrule\">Grade 3-4 (%)<footnote>Percentages are based on the number of patients with at least 1 post-baseline value available for that parameter</footnote></th></tr></thead><tfoot><tr><td colspan=\"2\" align=\"left\">Toxicity graded per NCI CTCAE v. 4.03</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\"><content styleCode=\"bold\">Hematology</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Lymphopenia</td><td styleCode=\"Rrule\">2.9</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\"><content styleCode=\"bold\">Electrolytes</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Hyponatremia</td><td styleCode=\"Rrule\">2.9</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Hypokalemia</td><td styleCode=\"Rrule\">1.5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Coagulation</content></td><td styleCode=\"Rrule\"/></tr><tr><td styleCode=\"Lrule Rrule\"> Activated partial thromboplastin time prolonged</td><td styleCode=\"Rrule\">1.9</td></tr></tbody></table>","<table width=\"85%\"><caption>Table 9: Adverse Reactions in &#x2265;10% of Patients with Locally Advanced or Metastatic NSCLC Receiving LIBTAYO and Chemotherapy in Study 16113</caption><col width=\"40%\" align=\"left\" valign=\"middle\"/><col width=\"24%\" align=\"center\" valign=\"middle\"/><col width=\"8%\" align=\"center\" valign=\"middle\"/><col width=\"18%\" align=\"center\" valign=\"middle\"/><col width=\"10%\" align=\"center\" valign=\"middle\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" rowspan=\"2\">Adverse Reactions</th><th styleCode=\"Rrule\" colspan=\"2\">LIBTAYO and Chemotherapy   (N=312)</th><th styleCode=\"Rrule\" colspan=\"2\">Placebo and Chemotherapy   (N=153)</th></tr><tr><th styleCode=\"Rrule\" align=\"center\">All Grades   %</th><th styleCode=\"Rrule\">Grades 3 or 4   %</th><th styleCode=\"Rrule\">All Grades   %</th><th styleCode=\"Rrule\">Grades 3 or 4   %</th></tr></thead><tfoot><tr><td colspan=\"5\" align=\"left\">Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v. 4.03</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">Skin and subcutaneous tissue disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Alopecia</td><td styleCode=\"Rrule\">37</td><td styleCode=\"Rrule\">0</td><td styleCode=\"Rrule\">43</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Rash<footnote>Rash is a composite term that includes rash, rash maculo-papular, dermatitis, psoriasis, rash papular, urticaria, dermatitis allergic, erythema, lichen planus, rash macular, rash pruritic, skin reaction, skin toxicity, skin exfoliation, and dermatitis acneiform</footnote></td><td styleCode=\"Rrule\">13</td><td styleCode=\"Rrule\">1.3</td><td styleCode=\"Rrule\">6</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">Musculoskeletal and connective tissue disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Musculoskeletal pain<footnote>Musculoskeletal pain is a composite term that includes arthralgia, back pain, pain in extremity, non-cardiac chest pain, myalgia, bone pain, musculoskeletal pain, neck pain, musculoskeletal chest pain, arthritis, and spinal pain</footnote></td><td styleCode=\"Rrule\">30</td><td styleCode=\"Rrule\">1.6</td><td styleCode=\"Rrule\">36</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">Gastrointestinal disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Nausea</td><td styleCode=\"Rrule\">25</td><td styleCode=\"Rrule\">0</td><td styleCode=\"Rrule\">16</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Constipation</td><td styleCode=\"Rrule\">14</td><td styleCode=\"Rrule\">0.3</td><td styleCode=\"Rrule\">11</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Vomiting</td><td styleCode=\"Rrule\">12</td><td styleCode=\"Rrule\">0</td><td styleCode=\"Rrule\">10</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Diarrhea</td><td styleCode=\"Rrule\">11</td><td styleCode=\"Rrule\">1.3</td><td styleCode=\"Rrule\">7</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">General disorders and administration site conditions</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Fatigue<footnote>Fatigue is a composite term that includes asthenia, fatigue, and malaise</footnote></td><td styleCode=\"Rrule\">23</td><td styleCode=\"Rrule\">3.8</td><td styleCode=\"Rrule\">18</td><td styleCode=\"Rrule\">2</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">Nervous system disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Peripheral neuropathy<footnote>Peripheral neuropathy is a composite term that includes peripheral sensory neuropathy, peripheral neuropathy, paresthesia, polyneuropathy, hypoesthesia, peripheral sensorimotor neuropathy, neuralgia, polyneuropathy in malignant disease, and toxic neuropathy</footnote></td><td styleCode=\"Rrule\">23</td><td styleCode=\"Rrule\">0</td><td styleCode=\"Rrule\">19</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">Metabolism and nutrition disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Decreased appetite</td><td styleCode=\"Rrule\">17</td><td styleCode=\"Rrule\">1</td><td styleCode=\"Rrule\">12</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">Investigations</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Weight decreased</td><td styleCode=\"Rrule\">11</td><td styleCode=\"Rrule\">1.3</td><td styleCode=\"Rrule\">8</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">Respiratory, thoracic, and mediastinal disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Dyspnea<footnote>Dyspnea is a composite term that includes dyspnea and dyspnea exertional</footnote></td><td styleCode=\"Rrule\">13</td><td styleCode=\"Rrule\">2.2</td><td styleCode=\"Rrule\">7</td><td styleCode=\"Rrule\">0.7</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">Psychiatric disorders</content></td></tr><tr><td styleCode=\"Lrule Rrule\"> Insomnia</td><td styleCode=\"Rrule\">11</td><td styleCode=\"Rrule\">0</td><td styleCode=\"Rrule\">7</td><td styleCode=\"Rrule\">0</td></tr></tbody></table>","<table width=\"85%\"><caption>Table 10: Grade 3 or 4 Laboratory Abnormalities Worsening from Baseline in &#x2265;1% of Patients with Locally Advanced or Metastatic NSCLC Receiving LIBTAYO and Chemotherapy in Study 16113</caption><col width=\"34%\" align=\"left\" valign=\"middle\"/><col width=\"34%\" align=\"center\" valign=\"middle\"/><col width=\"32%\" align=\"center\" valign=\"middle\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" rowspan=\"2\">Laboratory Abnormality</th><th styleCode=\"Rrule\">LIBTAYO and Chemotherapy</th><th styleCode=\"Rrule\">Placebo and Chemotherapy</th></tr><tr><th styleCode=\"Rrule\" align=\"center\" colspan=\"2\">Grades 3 or 4 (%)<footnote>The denominator used to calculate the rate varied from 134 to 299 based on the number of patients with a baseline value and at least one post-treatment value.</footnote></th></tr></thead><tfoot><tr><td colspan=\"3\" align=\"left\">Toxicity graded per NCI CTCAE v. 4.03</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Chemistry</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Hyperglycemia</td><td styleCode=\"Rrule\">4</td><td styleCode=\"Rrule\">1.5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Increased alanine aminotransferase</td><td styleCode=\"Rrule\">3</td><td styleCode=\"Rrule\">2.1</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Increased creatinine</td><td styleCode=\"Rrule\">2</td><td styleCode=\"Rrule\">1.4</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Hypoalbuminemia</td><td styleCode=\"Rrule\">1</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Hematology</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Anemia</td><td styleCode=\"Rrule\">10</td><td styleCode=\"Rrule\">7</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Neutrophil count decreased</td><td styleCode=\"Rrule\">10</td><td styleCode=\"Rrule\">8</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Lymphocyte count decreased</td><td styleCode=\"Rrule\">7</td><td styleCode=\"Rrule\">8</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> White blood cell decreased</td><td styleCode=\"Rrule\">6</td><td styleCode=\"Rrule\">4.1</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Platelet count decreased</td><td styleCode=\"Rrule\">4.7</td><td styleCode=\"Rrule\">0.7</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Electrolytes</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Hyponatremia</td><td styleCode=\"Rrule\">6</td><td styleCode=\"Rrule\">4.1</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Hypophosphatemia</td><td styleCode=\"Rrule\">3.4</td><td styleCode=\"Rrule\">7</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Hypocalcemia</td><td styleCode=\"Rrule\">3</td><td styleCode=\"Rrule\">2.1</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Hyperkalemia</td><td styleCode=\"Rrule\">2.7</td><td styleCode=\"Rrule\">2.7</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Hypermagnesemia</td><td styleCode=\"Rrule\">2.4</td><td styleCode=\"Rrule\">2.8</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Hypokalemia</td><td styleCode=\"Rrule\">2.3</td><td styleCode=\"Rrule\">1.4</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Hypercalcemia</td><td styleCode=\"Rrule\">1.7</td><td styleCode=\"Rrule\">0.7</td></tr><tr><td styleCode=\"Lrule Rrule\"> Hypernatremia</td><td styleCode=\"Rrule\">1</td><td styleCode=\"Rrule\">0</td></tr></tbody></table>","<table width=\"85%\"><caption>Table 11: Adverse Reactions in &#x2265;10% of Patients with Locally Advanced or Metastatic NSCLC Receiving LIBTAYO in Study 1624</caption><col width=\"40%\" align=\"left\" valign=\"top\"/><col width=\"15%\" align=\"center\" valign=\"top\"/><col width=\"15%\" align=\"center\" valign=\"top\"/><col width=\"15%\" align=\"center\" valign=\"top\"/><col width=\"15%\" align=\"center\" valign=\"top\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" rowspan=\"2\">Adverse Reactions</th><th styleCode=\"Rrule\" colspan=\"2\">LIBTAYO   N=355</th><th styleCode=\"Rrule\" colspan=\"2\">Chemotherapy   N=342</th></tr><tr><th styleCode=\"Rrule\" align=\"center\">All Grades   %</th><th styleCode=\"Rrule\">Grades 3-4   %</th><th styleCode=\"Rrule\">All Grades   %</th><th styleCode=\"Rrule\">Grades 3-4   %</th></tr></thead><tfoot><tr><td colspan=\"5\" align=\"left\">Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v.4.03</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">Musculoskeletal and connective tissue disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Musculoskeletal pain<footnote>Musculoskeletal pain is a composite term that includes back pain, arthralgia, pain in extremity, musculoskeletal pain, musculoskeletal chest pain, bone pain, myalgia, neck pain, spinal pain, and musculoskeletal stiffness</footnote></td><td styleCode=\"Rrule\">26</td><td styleCode=\"Rrule\">0.6 </td><td styleCode=\"Rrule\">27</td><td styleCode=\"Rrule\">1.5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">Skin and subcutaneous tissue disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Rash<footnote>Rash is a composite term that includes rash, dermatitis, urticaria, rash maculo-papular, erythema, rash erythematous, rash pruritic, psoriasis, autoimmune dermatitis, dermatitis acneiform, dermatitis allergic, dermatitis atopic, dermatitis bullous, drug eruption, dyshidrotic eczema, lichen planus, and skin reaction</footnote></td><td styleCode=\"Rrule\">15</td><td styleCode=\"Rrule\">1.4</td><td styleCode=\"Rrule\">6</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">Blood and lymphatic system disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Anemia</td><td styleCode=\"Rrule\">15</td><td styleCode=\"Rrule\">3.4</td><td styleCode=\"Rrule\">50</td><td styleCode=\"Rrule\">16</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">General disorders and administration site conditions</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Fatigue<footnote>Fatigue is a composite term that includes fatigue, asthenia, and malaise</footnote></td><td styleCode=\"Rrule\">14</td><td styleCode=\"Rrule\">1.1</td><td styleCode=\"Rrule\">26</td><td styleCode=\"Rrule\">2</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">Metabolism and nutrition disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Decreased appetite</td><td styleCode=\"Rrule\">12</td><td styleCode=\"Rrule\">0.6</td><td styleCode=\"Rrule\">18</td><td styleCode=\"Rrule\">0.3</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">Infections and infestations</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Pneumonia<footnote>Pneumonia is a composite term that includes atypical pneumonia, embolic pneumonia, lower respiratory tract infection, lung abscess, paracancerous pneumonia, pneumonia, pneumonia bacterial, and pneumonia klebsiella</footnote></td><td styleCode=\"Rrule\">11</td><td styleCode=\"Rrule\">5</td><td styleCode=\"Rrule\">12</td><td styleCode=\"Rrule\">5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\"><content styleCode=\"bold\">Respiratory, thoracic, and mediastinal disorders</content></td></tr><tr><td styleCode=\"Lrule Rrule\"> Cough<footnote>Cough is a composite term that includes cough and productive cough</footnote></td><td styleCode=\"Rrule\">11</td><td styleCode=\"Rrule\">0</td><td styleCode=\"Rrule\">8</td><td styleCode=\"Rrule\">0.3</td></tr></tbody></table>","<table width=\"80%\"><caption>Table 12: Grade 3 or 4 Laboratory Abnormalities Worsening from Baseline in &#x2265;1% of Patients with Locally Advanced or Metastatic NSCLC Receiving LIBTAYO in Study 1624</caption><col width=\"40%\" align=\"left\" valign=\"top\"/><col width=\"25%\" align=\"center\" valign=\"top\"/><col width=\"35%\" align=\"center\" valign=\"top\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" rowspan=\"2\">Laboratory Abnormality</th><th styleCode=\"Rrule\">LIBTAYO   N=355</th><th styleCode=\"Rrule\">Chemotherapy   N=342</th></tr><tr><th styleCode=\"Rrule\" colspan=\"2\" align=\"center\">Grades 3-4<footnote>Percentages are based on the number of patients with at least 1 post-baseline value available for that parameter</footnote>  %</th></tr></thead><tfoot><tr><td colspan=\"3\" align=\"left\">Toxicity graded per NCI CTCAE v. 4.03</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\"><content styleCode=\"bold\">Chemistry</content></td><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Increased aspartate aminotransferase</td><td styleCode=\"Rrule\">3.9</td><td styleCode=\"Rrule\">1.2</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Increased alanine aminotransferase</td><td styleCode=\"Rrule\">2.7</td><td styleCode=\"Rrule\">0.3</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Increased alkaline phosphatase</td><td styleCode=\"Rrule\">2.4</td><td styleCode=\"Rrule\">0.3</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Increased blood bilirubin</td><td styleCode=\"Rrule\">2.1</td><td styleCode=\"Rrule\">0.3</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Hypoalbuminemia</td><td styleCode=\"Rrule\">1.8</td><td styleCode=\"Rrule\">1.3</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Increased creatinine</td><td styleCode=\"Rrule\">1.2</td><td styleCode=\"Rrule\">1.6</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\"><content styleCode=\"bold\">Hematology</content></td><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Lymphopenia</td><td styleCode=\"Rrule\">7</td><td styleCode=\"Rrule\">9</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Anemia</td><td styleCode=\"Rrule\">2.7</td><td styleCode=\"Rrule\">16</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\"><content styleCode=\"bold\">Electrolytes</content></td><td styleCode=\"Rrule\"/></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Hyponatremia</td><td styleCode=\"Rrule\">6</td><td styleCode=\"Rrule\">7</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Hyperkalemia</td><td styleCode=\"Rrule\">4.2</td><td styleCode=\"Rrule\">1.9</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Hypocalcemia</td><td styleCode=\"Rrule\">3.9</td><td styleCode=\"Rrule\">3.4</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Hypophosphatemia</td><td styleCode=\"Rrule\">2.4</td><td styleCode=\"Rrule\">4.1</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Hypermagnesemia</td><td styleCode=\"Rrule\">2.1</td><td styleCode=\"Rrule\">1.6</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Hypokalemia</td><td styleCode=\"Rrule\">1.5</td><td styleCode=\"Rrule\">2.2</td></tr><tr><td styleCode=\"Lrule Rrule\">Hypercalcemia</td><td styleCode=\"Rrule\">1.2</td><td styleCode=\"Rrule\">2.2</td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). Immune-Mediated Adverse Reactions Advise patients that LIBTAYO can cause immune-mediated adverse reactions including the following [see Warnings and Precautions (5.1) ] : Pneumonitis: Advise patients to contact their healthcare provider immediately for signs or symptoms of pneumonitis, including new or worsening symptoms of cough, chest pain, or shortness of breath. Colitis: Advise patients to contact their healthcare provider immediately for signs or symptoms of colitis, including diarrhea, blood or mucus in stools, or severe abdominal pain. Hepatitis: Advise patients to contact their healthcare provider immediately for signs or symptoms of hepatitis. Endocrinopathies: Advise patients to contact their healthcare provider immediately for signs or symptoms of hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, or type 1 diabetes mellitus. Nephritis: Advise patients to contact their healthcare provider immediately for signs or symptoms of nephritis. Dermatologic Adverse Reactions: Advise patients to contact their healthcare provider immediately if they develop a new rash. Other Immune-Mediated Adverse Reactions: Advise patients that immune-mediated adverse reactions can occur and may involve any organ system, and to contact their healthcare provider immediately for any new or worsening signs or symptoms [see Warnings and Precautions (5.1) ]. Advise patients of the risk of solid organ transplant rejection and other transplant (including corneal graft) rejection and to contact their healthcare provider immediately for signs or symptoms of organ transplant rejection [see Warnings and Precautions (5.1) ]. Infusion-Related Reactions Advise patients to contact their healthcare provider immediately for signs or symptoms of infusion-related reactions [see Warnings and Precautions (5.2) ]. Complications of Allogeneic HSCT Advise patients to contact their healthcare provider immediately if they develop signs or symptoms of post-allogeneic HSCT complications [see Warnings and Precautions (5.3) ]. Embryo-Fetal Toxicity Advise females of reproductive potential that LIBTAYO can cause harm to a fetus and to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.4) and Use in Specific Populations (8.1 , 8.3) ]. Advise females of reproductive potential to use effective contraception during treatment and for at least 4 months after the last dose of LIBTAYO [see Use in Specific Populations (8.3) ] . Lactation Advise female patients not to breastfeed while taking LIBTAYO and for at least 4 months after the last dose [see Use in Specific Populations (8.2) ] ."],"spl_unclassified_section":["Manufactured by: Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 U.S. License No. 1760 Marketed by: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591) ©2025 Regeneron Pharmaceuticals, Inc. All rights reserved."],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Administer LIBTAYO as an intravenous infusion over 30 minutes after dilution. ( 2.2 ) Metastatic and locally advanced CSCC and BCC: 350 mg every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months. ( 2.2 ) Adjuvant treatment of CSCC at high risk of recurrence after surgery and radiation: 350 mg every 3 weeks for 12 weeks followed by 700 mg every 6 weeks until disease recurrence, unacceptable toxicity, or up to 48 weeks of total therapy, or 350 mg every 3 weeks until disease recurrence, unacceptable toxicity, or up to 48 weeks of total therapy. ( 2.2 ) NSCLC: 350 mg every 3 weeks until disease progression or unacceptable toxicity. ( 2.2 ) 2.1 Patient Selection for NSCLC Select patients with locally advanced or metastatic NSCLC for treatment with LIBTAYO as a single agent based on PD-L1 expression on tumor cells [see Clinical Studies (14.3) ]. Information on FDA-approved tests for the detection of PD-L1 expression is available at: http://www.fda.gov/CompanionDiagnostics. 2.2 Recommended Dosage The recommended dosages of LIBTAYO are presented in Table 1. Refer to the Prescribing Information for the agents administered in combination with LIBTAYO for recommended dosing information, as appropriate. Table 1: Recommended Dosages of LIBTAYO as a Single Agent or in Combination with Other Agents Indication Recommended dosage of LIBTAYO as an intravenous infusion Duration of Treatment Adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) 350 mg every 3 weeks Until disease progression, unacceptable toxicity, or up to 24 months. Adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation 350 mg every 3 weeks for 12 weeks, followed by 700 mg every 6 weeks Or 350 mg every 3 weeks Until disease recurrence, unacceptable toxicity, or up to 48 weeks. Adults with locally advanced basal cell carcinoma (laBCC) or metastatic BCC (mBCC) 350 mg every 3 weeks Until disease progression, unacceptable toxicity, or up to 24 months. Adults with non-small cell lung cancer (NSCLC) Single-agent or in combination with platinum-based chemotherapy 350 mg every 3 weeks Until disease progression or unacceptable toxicity. 2.3 Dosage Modifications for Adverse Reactions No dose reduction for LIBTAYO is recommended. In general, withhold LIBTAYO for severe (Grade 3) immune-mediated adverse reactions. Permanently discontinue LIBTAYO for life-threatening (Grade 4) immune-mediated adverse reactions, recurrent severe (Grade 3) immune-mediated reactions that require systemic immunosuppressive treatment, or an inability to reduce corticosteroid dose to 10 mg or less of prednisone equivalent per day within 12 weeks of initiating steroids. Dosage modifications for LIBTAYO for adverse reactions that require management different from these general guidelines are summarized in Table 2. Table 2: Recommended Dosage Modifications for Adverse Reactions Adverse Reaction Severity Based on National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 Dosage Modifications ALT=alanine aminotransferase, AST=aspartate aminotransferase, ULN=upper limit of normal, SJS=Stevens-Johnson Syndrome, TEN=toxic epidermal necrolysis, DRESS=Drug Rash with Eosinophilia and Systemic Symptoms Immune-Mediated Adverse Reactions [see Warnings and Precautions (5.1) ] Pneumonitis Grade 2 Withhold Resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper. Permanently discontinue if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg per day (or equivalent) within 12 weeks of initiating steroids. Grade 3 or 4 Permanently discontinue Colitis Grade 2 or 3 Withhold Grade 4 Permanently discontinue Hepatitis with no tumor involvement of the liver AST or ALT increases to more than 3 and up to 8 times ULN or Total bilirubin increases to more than 1.5 and up to 3 times the ULN Withhold AST or ALT increases to more than 8 times the ULN or Total bilirubin increases to more than 3 times the ULN Permanently discontinue Hepatitis with tumor involvement of the liver If AST and ALT are less than or equal to ULN at baseline, withhold or permanently discontinue LIBTAYO based on recommendations for hepatitis with no liver involvement Baseline AST or ALT is more than 1 and up to 3 times ULN and increases to more than 5 and up to 10 times ULN or Baseline AST or ALT is more than 3 and up to 5 times ULN and increases to more than 8 and up to 10 times ULN Withhold AST or ALT increases to more than 10 times ULN or Total bilirubin increases to more than 3 times ULN Permanently discontinue Endocrinopathies Grade 3 or 4 Withhold until clinically stable or permanently discontinue depending on severity Nephritis with Renal Dysfunction Grade 2 or 3 increased blood creatinine Withhold Grade 4 increased blood creatinine Permanently discontinue Exfoliative Dermatologic Conditions Suspected SJS, TEN, or DRESS Withhold Confirmed SJS, TEN, or DRESS Permanently discontinue Myocarditis Grade 2, 3 or 4 Permanently discontinue Neurological Toxicities Grade 2 Withhold Grade 3 or 4 Permanently discontinue Other Adverse Reactions Infusion-related reactions [see Warnings and Precautions (5.2) ] Grade 1 or 2 Interrupt or slow the rate of infusion Grade 3 or 4 Permanently discontinue 2.4 Preparation and Administration Visually inspect for particulate matter and discoloration prior to administration. LIBTAYO is a clear to slightly opalescent, colorless to pale yellow solution that may contain trace amounts of translucent to white particles. Discard the vial if the solution is cloudy, discolored or contains extraneous particulate matter other than trace amounts of translucent to white particles. Preparation Do not shake the vial(s). Withdraw the required volume from the vial(s) of LIBTAYO and transfer into an intravenous (IV) bag containing 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP to a final concentration between 1 mg/mL to 20 mg/mL. Mix diluted solution by gentle inversion. Do not shake. Discard any unused portion left in the vial(s). Storage of Diluted Solution Store at room temperature up to 25°C (77°F) for no more than 8 hours from the time of preparation to the end of the infusion or under refrigeration at 2°C to 8°C (36°F to 46°F) for no more than 10 days from the time of preparation to the end of infusion. Allow the diluted solution to come to room temperature prior to administration. Do not freeze. Administration Administer by intravenous infusion over 30 minutes through an intravenous line containing a sterile, in-line or add-on 0.2-micron to 5-micron filter."],"spl_product_data_elements":["LIBTAYO cemiplimab-rwlc CEMIPLIMAB CEMIPLIMAB HISTIDINE HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE PROLINE POLYSORBATE 80 SUCROSE WATER"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Injection: 350 mg/7 mL (50 mg/mL), clear to slightly opalescent, colorless to pale yellow solution that may contain trace amounts of translucent to white particles in a single-dose vial. Injection: 350 mg/7 mL (50 mg/mL) solution in a single-dose vial. ( 3 )"],"recent_major_changes_table":["<table width=\"100%\" styleCode=\"Noautorules\"><col width=\"80%\" align=\"left\" valign=\"top\"/><col width=\"20%\" align=\"right\" valign=\"top\"/><tbody><tr><td>Indications and Usage (<linkHtml href=\"#S1.1\">1.1</linkHtml>)</td><td>10/2025 </td></tr><tr><td>Dosage and Administration (<linkHtml href=\"#S2.2\">2.2</linkHtml>)</td><td>10/2025 </td></tr></tbody></table>"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on its mechanism of action, LIBTAYO can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no available data on the use of LIBTAYO in pregnant women. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death (see Data ) . Human IgG4 immunoglobulins (IgG4) are known to cross the placenta; therefore, LIBTAYO has the potential to be transmitted from the mother to the developing fetus. Advise women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Animal reproduction studies have not been conducted with LIBTAYO to evaluate its effect on reproduction and fetal development. A central function of the PD-1/PD-L1 pathway is to preserve pregnancy by maintaining maternal immune tolerance to the fetus. In murine models of pregnancy, blockade of PD-L1 signaling has been shown to disrupt tolerance to the fetus and to result in an increase in fetal loss; therefore, potential risks of administering LIBTAYO during pregnancy include increased rates of abortion or stillbirth. As reported in the literature, there were no malformations related to the blockade of PD-1/PD-L1 signaling in the offspring of these animals; however, immune-mediated disorders occurred in PD-1 and PD-L1 knockout mice. Based on its mechanism of action, fetal exposure to cemiplimab-rwlc may increase the risk of developing immune-mediated disorders or altering the normal immune response. 8.2 Lactation Risk Summary There is no information regarding the presence of cemiplimab-rwlc in human milk, or its effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for at least 4 months after the last dose of LIBTAYO. 8.3 Females and Males of Reproductive Potential Pregnancy Testing Verify pregnancy status in females of reproductive potential prior to initiating LIBTAYO [see Use in Specific Populations (8.1) ] . Contraception LIBTAYO can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] . Females Advise females of reproductive potential to use effective contraception during treatment with LIBTAYO and for at least 4 months after the last dose. 8.4 Pediatric Use The safety and effectiveness of LIBTAYO have not been established in pediatric patients. The safety and efficacy of LIBTAYO as a single agent (Part 1, N=25) or in combination with radiation therapy (Part 2, N=22) were evaluated but not established in a two-part, open-label, multi-center trial (Study 1690, NCT03690869) in pediatric patients (birth to < 17 years) with relapsed or refractory solid tumors (Part 1) or relapsed or refractory CNS tumors (Parts 1 and 2) or newly diagnosed CNS tumors (Part 2). No new safety signals were observed in these pediatric patients. Cemiplimab exposure in 46 pediatric patients aged 1 to < 17 years was within the range of values previously observed in adults given a similar dose based on body weight. 8.5 Geriatric Use LIBTAYO as a Single Agent Of the 1281 patients with advanced cancers who received LIBTAYO as a single agent in clinical studies, 26% were 65 years up to 75 years and 22% were 75 years or older. No overall differences in safety or effectiveness were observed between these patients and younger patients. Of the 358 patients with mCSCC or laCSCC who received LIBTAYO as a single agent in Study 1540, 30% were 65 years up to 75 years and 48% were 75 years or older. No overall differences in safety or effectiveness were observed between these patients and younger patients. Of the 205 adult patients with CSCC at high-risk of recurrence who received LIBTAYO as a single agent in the C-POST study, 39% were 65 years up to 75 years and 35% were 75 years or older. No overall differences in safety or effectiveness were observed between these patients and younger patients. Of the 138 patients with BCC who received LIBTAYO as a single agent in Study 1620, 27% were 65 years up to 75 years, and 31% were 75 years or older. No overall differences in safety or effectiveness were observed between these patients and younger patients. LIBTAYO in Combination with Platinum-based Chemotherapy Of the 312 patients with NSCLC who received LIBTAYO in combination with platinum-based chemotherapy in Study 16113, 35% were 65 years up to 75 years and 6% were 75 years or older. No overall differences in safety or effectiveness were observed between these patients and younger patients."],"dosage_and_administration_table":["<table width=\"80%\"><caption>Table 1: Recommended Dosages of LIBTAYO as a Single Agent or in Combination with Other Agents</caption><col width=\"34%\" align=\"left\" valign=\"top\"/><col width=\"33%\" align=\"left\" valign=\"top\"/><col width=\"33%\" align=\"left\" valign=\"top\"/><thead><tr><th styleCode=\"Lrule Rrule\"><content styleCode=\"xmChange\">Indication</content></th><th styleCode=\"Rrule\">Recommended dosage of LIBTAYO as an intravenous infusion</th><th styleCode=\"Rrule\">Duration of Treatment</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"xmChange\">Adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC)</content></td><td styleCode=\"Rrule\">350 mg every 3 weeks</td><td styleCode=\"Rrule\">Until disease progression, unacceptable toxicity, or up to 24 months.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"xmChange\">Adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation</content></td><td styleCode=\"Rrule\">350 mg every 3 weeks for 12 weeks, followed by 700 mg every 6 weeks   Or   350 mg every 3 weeks</td><td styleCode=\"Rrule\">Until disease recurrence, unacceptable toxicity, or up to 48 weeks.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"xmChange\">Adults with locally advanced basal cell carcinoma (laBCC) or metastatic BCC (mBCC)</content></td><td styleCode=\"Rrule\">350 mg every 3 weeks</td><td styleCode=\"Rrule\">Until disease progression, unacceptable toxicity, or up to 24 months.</td></tr><tr><td styleCode=\"Lrule Rrule\"><content styleCode=\"xmChange\">Adults with non-small cell lung cancer (NSCLC)<footnote>Single-agent or in combination with platinum-based chemotherapy</footnote></content></td><td styleCode=\"Rrule\">350 mg every 3 weeks</td><td styleCode=\"Rrule\">Until disease progression or unacceptable toxicity.</td></tr></tbody></table>","<table width=\"80%\"><caption>Table 2: Recommended Dosage Modifications for Adverse Reactions</caption><col width=\"34%\" align=\"left\" valign=\"middle\"/><col width=\"32%\" align=\"left\" valign=\"middle\"/><col width=\"34%\" align=\"left\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\">Adverse Reaction</th><th styleCode=\"Rrule\">Severity<footnote>Based on National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0</footnote></th><th styleCode=\"Rrule\">Dosage Modifications</th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"3\">ALT=alanine aminotransferase, AST=aspartate aminotransferase, ULN=upper limit of normal, SJS=Stevens-Johnson Syndrome, TEN=toxic epidermal necrolysis, DRESS=Drug Rash with Eosinophilia and Systemic Symptoms</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Immune-Mediated Adverse Reactions</content><content styleCode=\"italics\"> [see <linkHtml href=\"#S5.1\">Warnings and Precautions (5.1)</linkHtml>]</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\">Pneumonitis </td><td styleCode=\"Rrule\">Grade 2</td><td styleCode=\"Rrule\">Withhold<footnote ID=\"t2f1\">Resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper. Permanently discontinue if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg per day (or equivalent) within 12 weeks of initiating steroids.</footnote></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">Grade 3 or 4</td><td styleCode=\"Rrule\">Permanently discontinue</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\">Colitis</td><td styleCode=\"Rrule\">Grade 2 or 3</td><td styleCode=\"Rrule\">Withhold<footnoteRef IDREF=\"t2f1\"/></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">Grade 4</td><td styleCode=\"Rrule\">Permanently discontinue</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\">Hepatitis with no tumor involvement of the liver</td><td styleCode=\"Rrule\">AST or ALT increases to more than 3 and up to 8 times ULN   or   Total bilirubin increases to more than 1.5 and up to 3 times the ULN</td><td styleCode=\"Rrule\">Withhold<footnoteRef IDREF=\"t2f1\"/></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">AST or ALT increases to more than 8 times the ULN   or   Total bilirubin increases to more than 3 times the ULN</td><td styleCode=\"Rrule\">Permanently discontinue</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\">Hepatitis with tumor involvement of the liver<footnote>If AST and ALT are less than or equal to ULN at baseline, withhold or permanently discontinue LIBTAYO based on recommendations for hepatitis with no liver involvement</footnote></td><td styleCode=\"Rrule\">Baseline AST or ALT is more than 1 and up to 3 times ULN and increases to more than 5 and up to 10 times ULN   or   Baseline AST or ALT is more than 3 and up to 5 times ULN and increases to more than 8 and up to 10 times ULN</td><td styleCode=\"Rrule\">Withhold<footnoteRef IDREF=\"t2f1\"/></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">AST or ALT increases to more than 10 times ULN   or   Total bilirubin increases to more than 3 times ULN</td><td styleCode=\"Rrule\">Permanently discontinue</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Endocrinopathies</td><td styleCode=\"Rrule\">Grade 3 or 4</td><td styleCode=\"Rrule\">Withhold until clinically stable or permanently discontinue depending on severity</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\">Nephritis with Renal Dysfunction</td><td styleCode=\"Rrule\">Grade 2 or 3 increased blood creatinine</td><td styleCode=\"Rrule\">Withhold<footnoteRef IDREF=\"t2f1\"/></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">Grade 4 increased blood creatinine</td><td styleCode=\"Rrule\">Permanently discontinue</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\">Exfoliative Dermatologic Conditions</td><td styleCode=\"Rrule\">Suspected SJS, TEN, or DRESS</td><td styleCode=\"Rrule\">Withhold<footnoteRef IDREF=\"t2f1\"/></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">Confirmed SJS, TEN, or DRESS</td><td styleCode=\"Rrule\">Permanently discontinue</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Myocarditis</td><td styleCode=\"Rrule\">Grade 2, 3 or 4</td><td styleCode=\"Rrule\">Permanently discontinue</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\">Neurological Toxicities</td><td styleCode=\"Rrule\">Grade 2</td><td styleCode=\"Rrule\">Withhold<footnoteRef IDREF=\"t2f1\"/></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule\">Grade 3 or 4</td><td styleCode=\"Rrule\">Permanently discontinue</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"3\"><content styleCode=\"bold\">Other Adverse Reactions</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\">Infusion-related reactions <content styleCode=\"italics\">[see <linkHtml href=\"#S5.2\">Warnings and Precautions (5.2)</linkHtml>]</content></td><td styleCode=\"Rrule\">Grade 1 or 2</td><td styleCode=\"Rrule\">Interrupt or slow the rate of infusion</td></tr><tr><td styleCode=\"Rrule\">Grade 3 or 4</td><td styleCode=\"Rrule\">Permanently discontinue</td></tr></tbody></table>"],"animal_pharmacology_and_or_toxicology":["13.2 Animal Toxicology and/or Pharmacology In animal models, inhibition of PD-L1/PD-1 signaling increased the severity of some infections and enhanced inflammatory responses. M. tuberculosis –infected PD-1 knockout mice exhibit markedly decreased survival compared with wild-type controls, which correlated with increased bacterial proliferation and inflammatory responses in these animals. PD-L1 and PD-1 knockout mice and mice receiving PD-L1 blocking antibody have also shown decreased survival following infection with lymphocytic choriomeningitis virus."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 350 mg/7 mL Vial Carton NDC 61755-008-01 Rx only LIBTAYO ® (cemiplimab-rwlc) Injection 350 mg/7 mL (50 mg/mL) For Intravenous Infusion After Dilution Single-Dose Vial Discard unused portion. Do not use vial if seal is broken or missing. Dispense the enclosed Medication Guide to each patient. REGENERON PRINCIPAL DISPLAY PANEL - 350 mg/7 mL Vial Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No studies have been performed to assess the potential of cemiplimab-rwlc for carcinogenicity or genotoxicity. In a 3-month repeat-dose toxicology study in sexually mature cynomolgus monkeys, there were no cemiplimab-rwlc-related effects on fertility parameters (menstrual cycle, semen analysis, or testicular measurements) or in male or female reproductive organs at doses up to the highest dose tested, 50 mg/kg/week (approximately 5.5 to 25.5 times the human exposure based on AUC at the clinical dose of 350 mg once every 3 weeks)."]},"tags":[{"label":"Monoclonal Antibody","category":"modality"},{"label":"Programmed cell death protein 1","category":"target"},{"label":"PDCD1","category":"gene"},{"label":"L01FF06","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Malignant tumor of cervix","category":"indication"},{"label":"Metastatic basal cell carcinoma","category":"indication"},{"label":"Non-small cell lung cancer without mutation in epidermal growth factor receptor","category":"indication"},{"label":"Nonsmall cell lung cancer without mutation in epidermal growth factor receptor","category":"indication"},{"label":"Squamous cell carcinoma","category":"indication"},{"label":"Regeneron Pharmaceuticals ","category":"company"},{"label":"Approved 2010s","category":"decade"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Immunological","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"144 reports"},{"date":"","signal":"DISEASE PROGRESSION","source":"FDA FAERS","actionTaken":"126 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"96 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"81 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"71 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"56 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"55 reports"},{"date":"","signal":"PRURITUS","source":"FDA FAERS","actionTaken":"47 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"44 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"44 reports"}],"commonSideEffects":[{"effect":"fatigue","drugRate":"≥20%","_validated":true,"placeboRate":""},{"effect":"rash","drugRate":"≥20%","_validated":true,"placeboRate":""},{"effect":"musculoskeletal pain","drugRate":"≥20%","_validated":true,"placeboRate":""},{"effect":"diarrhea","drugRate":"≥20%","_validated":true,"placeboRate":""},{"effect":"pruritus","drugRate":"≥20%","_validated":true,"placeboRate":""},{"effect":"nausea","drugRate":"≥20%","_validated":true,"placeboRate":""}],"specialPopulations":{"Pregnancy":"Risk SummaryBased on its mechanism of action, LIBTAYO can cause fetal harm when administered to pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data on the use of LIBTAYO in pregnant women. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death (see Data). Human IgG4 immunoglobulins (IgG4) are known to cross the placenta; therefore, LIBTAYO has the potential to be transmitted from the mother to the developing fetus. Advise women of the potential risk to fetus.In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.. Data. Animal DataAnimal reproduction studies have not been conducted with LIBTAYO to evaluate its effect on reproduction and fetal development. central function of the PD-1/PD-L1 pathway is to preserve pregnancy by maintaining maternal immune tolerance to the fetus. In murine models of pregnancy, blockade of PD-L1 signaling has been shown to disrupt tolerance to the fetus and to result in an increase in fetal loss; therefore, potential risks of administering LIBTAYO during pregnancy include increased rates of abortion or stillbirth. As reported in the literature, there were no malformations related to the blockade of PD-L1 signaling in animal studies.","Geriatric use":"Of the 810 patients who received LIBTAYO in clinical studies, 32% were 65 years up to 75 years and 22% were 75 years or older. No overall differences in safety or effectiveness were observed between these patients and younger patients.Of the 219 patients with mCSCC or laCSCC who received LIBTAYO in clinical studies, 34% were 65 years up to 75 years and 41% were 75 years or older. No overall differences in safety or effectiveness were observed between these patients and younger ","Paediatric use":"The safety and effectiveness of LIBTAYO have not been established in pediatric patients."},"discontinuationRates":[{"trial":"Study 1540","drugArm":"12%","placeboArm":"","commonReason":"adverse reaction"}],"seriousAdverseEvents":[{"event":"pneumonia","detail":"serious adverse reaction","severity":"serious","incidence":"3.6%"},{"event":"skin infection","detail":"serious adverse reaction","severity":"serious","incidence":"3.6%"},{"event":"pneumonitis","detail":"serious adverse reaction","severity":"serious","incidence":"2.8%"},{"event":"infections","detail":"fatal adverse reaction","severity":"fatal","incidence":"2.2%"}]},"trials":[],"aliases":[],"company":"Regeneron Pharmaceuticals ","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CEMIPLIMAB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:45:43.742523+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:45:50.557059+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:45:43.767495+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:45:35.837114+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEMIPLIMAB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:45:51.386382+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:45:34.522875+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:45:34.522906+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:45:52.838799+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action Binding of the PD-1 ligands PD-L1 and PD-L2 to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Cemiplimab-rwlc is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:46:07.031376+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Programmed cell death protein 1 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:45:51.958486+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297723/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:45:51.855751+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling. Severe and Fatal Immune-Mediated Adverse Reactions [see Warnings and Precautions (5.1) ] Infusion-Related Reactions [see Warnings and Precautions (5.2) ] Complications of Allogeneic HSCT [see Warnings and Precautions (5.3) ] Most common adverse reactions (≥15%): LIBTAYO as a single agent in mCSCC or laCSCC, m BCC or laBCC, and NSCLC with high PD-L1 expression : Fatigue, musculoskeletal pain, rash","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:46:28.117574+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"BLA761097","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:45:34.522911+00:00"}},"allNames":"libtayo","offLabel":[],"synonyms":["cemiplimab","libtayo","REGN2810","cemiplimab-rwlc"],"timeline":[{"date":"2018-09-28","type":"positive","source":"DrugCentral","milestone":"FDA approval (Regeneron Pharmaceuticals )"},{"date":"2019-06-28","type":"positive","source":"DrugCentral","milestone":"EMA approval (Regeneron Ireland U.C.)"},{"date":"2022-12-23","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Sanofi K.K.)"}],"aiSummary":"Libtayo (cemiplimab) is a monoclonal antibody developed by Regeneron Pharmaceuticals, targeting the programmed cell death protein 1 (PD-1). It works by blocking the PD-1 receptor, allowing the immune system to recognize and attack cancer cells. Libtayo is approved to treat various types of cancer, including cervical cancer, basal cell carcinoma, and non-small cell lung cancer. It remains a patented product, and its commercial status is unchanged. Key safety considerations include immune-mediated adverse reactions and potential liver damage.","brandName":"Libtayo","ecosystem":[{"indication":"Malignant tumor of cervix","otherDrugs":[{"name":"bleomycin","slug":"bleomycin","company":"Bristol Myers Squibb"},{"name":"paclitaxel","slug":"paclitaxel","company":"Hq Spclt Pharma"},{"name":"topotecan","slug":"topotecan","company":"Novartis Pharms Corp"}],"globalPrevalence":null},{"indication":"Metastatic basal cell carcinoma","otherDrugs":[],"globalPrevalence":null},{"indication":"Non-small cell lung cancer without mutation in epidermal growth factor receptor","otherDrugs":[],"globalPrevalence":2200000},{"indication":"Nonsmall cell lung cancer without mutation in epidermal growth factor receptor","otherDrugs":[],"globalPrevalence":960000},{"indication":"Squamous cell carcinoma","otherDrugs":[{"name":"bleomycin","slug":"bleomycin","company":"Bristol Myers Squibb"}],"globalPrevalence":510000}],"mechanism":{"target":"PD-1","novelty":"Follow-on","targets":[{"gene":"PDCD1","source":"DrugCentral","target":"Programmed cell death protein 1","protein":"Programmed cell death protein 1"}],"modality":"Monoclonal antibody","explanation":"Cemiplimab-rwlc works by binding to the PD-1 receptor on T cells, preventing it from interacting with its ligands PD-L1 and PD-L2. This blockage releases the inhibition of T-cell activity, allowing the immune system to better recognize and attack tumor cells.","oneSentence":"Cemiplimab-rwlc binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors.","technicalDetail":"Binding of PD-1 ligands PD-L1 and PD-L2 to the PD-1 receptor on T cells inhibits T-cell proliferation and cytokine production. Cemiplimab-rwlc, a recombinant human IgG4 monoclonal antibody, binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, thereby releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response."},"commercial":{"launchDate":"2018","revenueYear":2025,"_launchSource":"DrugCentral (FDA 2018-09-28, REGENERON PHARMACEUTICALS )","annualRevenue":1452,"revenueSource":"Verified: Regeneron 8-K FY2025","revenueCurrency":"USD","revenueConfidence":"verified","revenueExtractedAt":"2026-04-01T11:47:26.572336","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5317","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CEMIPLIMAB","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEMIPLIMAB","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T02:46:23.657217","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T00:46:30.569644+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"nivolumab","drugSlug":"nivolumab","fdaApproval":"2014-12-22","relationship":"same-class"},{"drugName":"pembrolizumab","drugSlug":"pembrolizumab","fdaApproval":"2014-09-04","relationship":"same-class"},{"drugName":"durvalumab","drugSlug":"durvalumab","fdaApproval":"2017-05-01","relationship":"same-class"},{"drugName":"avelumab","drugSlug":"avelumab","fdaApproval":"2017-03-23","relationship":"same-class"},{"drugName":"atezolizumab","drugSlug":"atezolizumab","fdaApproval":"2016-05-18","relationship":"same-class"},{"drugName":"dostarlimab","drugSlug":"dostarlimab","fdaApproval":"2021-04-22","relationship":"same-class"},{"drugName":"retifanlimab","drugSlug":"retifanlimab","fdaApproval":"2023-03-22","relationship":"same-class"}],"genericName":"cemiplimab","indications":{"approved":[{"name":"Malignant tumor of cervix","source":"DrugCentral","snomedId":363354003,"regulator":"FDA"},{"name":"Metastatic basal cell carcinoma","source":"DrugCentral","snomedId":40641000146101,"regulator":"FDA"},{"name":"Non-small cell lung cancer without mutation in epidermal growth factor receptor","source":"DrugCentral","snomedId":703230006,"regulator":"FDA","usPrevalence":236000,"globalPrevalence":2200000,"prevalenceMethod":"curated","prevalenceSource":"IARC GLOBOCAN, 2022"},{"name":"Nonsmall cell lung cancer without mutation in epidermal growth factor receptor","source":"DrugCentral","snomedId":703230006,"regulator":"FDA","prevalenceClass":"1-5 / 10 000","globalPrevalence":960000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (European Medicines Agency 2018[INST])"},{"name":"Squamous cell carcinoma","source":"DrugCentral","snomedId":402815007,"regulator":"FDA","usPrevalence":null,"globalPrevalence":510000,"prevalenceMethod":"curated","prevalenceSource":"IARC GLOBOCAN, 2022"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"nivolumab","brandName":"nivolumab","genericName":"nivolumab","approvalYear":"2014","relationship":"same-class"},{"drugId":"pembrolizumab","brandName":"pembrolizumab","genericName":"pembrolizumab","approvalYear":"2014","relationship":"same-class"},{"drugId":"durvalumab","brandName":"durvalumab","genericName":"durvalumab","approvalYear":"2017","relationship":"same-class"},{"drugId":"avelumab","brandName":"avelumab","genericName":"avelumab","approvalYear":"2017","relationship":"same-class"},{"drugId":"atezolizumab","brandName":"atezolizumab","genericName":"atezolizumab","approvalYear":"2016","relationship":"same-class"},{"drugId":"dostarlimab","brandName":"dostarlimab","genericName":"dostarlimab","approvalYear":"2021","relationship":"same-class"},{"drugId":"retifanlimab","brandName":"retifanlimab","genericName":"retifanlimab","approvalYear":"2023","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03132636","phase":"PHASE2","title":"PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","isPivotal":true,"startDate":"2017-06-29","conditions":["Carcinoma, Basal Cell"],"enrollment":138,"completionDate":"2023-04-27"},{"nctId":"NCT02760498","phase":"PHASE2","title":"Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","isPivotal":true,"startDate":"2016-04-07","conditions":["Advanced Cutaneous Squamous Cell Carcinoma"],"enrollment":432,"completionDate":"2023-10-18"},{"nctId":"NCT02383212","phase":"PHASE1","title":"Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","isPivotal":true,"startDate":"2015-02-02","conditions":["Advanced Cancer","Advanced Malignancies"],"enrollment":398,"completionDate":"2019-11-18"},{"nctId":"NCT07020065","phase":"PHASE2","title":"Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%","status":"NOT_YET_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2026-05","conditions":["Metastatic NSCLC - Non-Small Cell Lung Cancer"],"enrollment":156,"completionDate":"2030-03"},{"nctId":"NCT06980038","phase":"PHASE2","title":"Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-21","conditions":["Head and Neck Squamous Cell Carcinoma","Hypopharyngeal Squamous Cell Carcinoma","Laryngeal Squamous Cell Carcinoma","Nasal Cavity Squamous Cell Carcinoma","Oral Cavity Squamous Cell Carcinoma","Oropharyngeal Squamous Cell Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma","Recurrent Hypopharyngeal Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Nasal Cavity Squamous Cell Carcinoma","Recurrent Oral Cavity Squamous Cell Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma","Stage III Laryngeal Cancer AJCC v8","Stage III Lip and Oral Cavity Cancer AJCC v8","Stage III Nasopharyngeal Carcinoma AJCC v8","Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IVA Laryngeal Cancer AJCC v8","Stage IVA Lip and Oral Cavity Cancer AJCC v8","Stage IVA Nasopharyngeal Carcinoma AJCC v8","Stage IVB Laryngeal Cancer AJCC v8","Stage IVB Lip and Oral Cavity Cancer AJCC v8"],"enrollment":44,"completionDate":"2027-11-24"},{"nctId":"NCT07147231","phase":"PHASE1,PHASE2","title":"Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461) in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-31","conditions":["Metastatic Colorectal Adenocarcinoma","Refractory Colorectal Adenocarcinoma","Stage III Colorectal Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","Unresectable Colorectal Adenocarcinoma"],"enrollment":86,"completionDate":"2027-09-30"},{"nctId":"NCT06594991","phase":"PHASE2","title":"A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-09-10","conditions":["Advanced Melanoma"],"enrollment":88,"completionDate":"2027-09"},{"nctId":"NCT03969004","phase":"PHASE3","title":"Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2019-06-04","conditions":["Cutaneous Squamous Cell Carcinoma"],"enrollment":415,"completionDate":"2028-01-07"},{"nctId":"NCT07195734","phase":"PHASE2","title":"Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-09","conditions":["Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Locally Recurrent Head and Neck Squamous Cell Carcinoma","Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma","Locally Recurrent Laryngeal Squamous Cell Carcinoma","Locally Recurrent Oral Cavity Squamous Cell Carcinoma","Locally Recurrent Oropharyngeal Squamous Cell Carcinoma","Stage II Laryngeal Cancer AJCC v8","Stage II Lip and Oral Cavity Cancer AJCC v8","Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage III Laryngeal Cancer AJCC v8","Stage III Lip and Oral Cavity Cancer AJCC v8","Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IVA Laryngeal Cancer AJCC v8","Stage IVA Lip and Oral Cavity Cancer AJCC v8","Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IVB Laryngeal Cancer AJCC v8","Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8"],"enrollment":180,"completionDate":"2033-02-01"},{"nctId":"NCT06568172","phase":"PHASE3","title":"Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-02-18","conditions":["Eyelid Squamous Cell Carcinoma","Recurrent Eyelid Squamous Cell Carcinoma","Recurrent Skin Acantholytic Squamous Cell Carcinoma","Recurrent Skin Clear Cell Squamous Cell Carcinoma","Recurrent Skin Lymphoepithelial Carcinoma","Recurrent Skin Spindle Cell Squamous Cell Carcinoma","Recurrent Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation","Resectable Eyelid Squamous Cell Carcinoma","Resectable Skin Acantholytic Squamous Cell Carcinoma","Resectable Skin Clear Cell Squamous Cell Carcinoma","Resectable Skin Lymphoepithelial Carcinoma","Resectable Skin Spindle Cell Squamous Cell Carcinoma","Resectable Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation","Skin Acantholytic Squamous Cell Carcinoma","Skin Clear Cell Squamous Cell Carcinoma","Skin Lymphoepithelial Carcinoma","Skin Spindle Cell Squamous Cell Carcinoma","Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation","Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8","Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8"],"enrollment":420,"completionDate":"2031-08-14"},{"nctId":"NCT07422363","phase":"PHASE1","title":"Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-28","conditions":["Recurrent Glioblastoma, IDH-Wildtype","Recurrent Gliosarcoma","Recurrent WHO Grade 4 Glioma"],"enrollment":30,"completionDate":"2027-02-28"},{"nctId":"NCT06418724","phase":"PHASE2","title":"Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2026-07-30","conditions":["Locally Advanced Cutaneous Squamous Cell Carcinoma"],"enrollment":27,"completionDate":"2030-12-01"},{"nctId":"NCT03017820","phase":"PHASE1","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-04-04","conditions":["B-Cell Non-Hodgkin Lymphoma","Histiocytic and Dendritic Cell Neoplasm","Myelodysplastic Syndrome","Previously Treated Myelodysplastic Syndrome","Recurrent Adult Acute Myeloid Leukemia","Recurrent Anaplastic Large Cell Lymphoma","Recurrent Angioimmunoblastic T-Cell Lymphoma","Recurrent Mycosis Fungoides","Recurrent Plasma Cell Myeloma","Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Recurrent T-Cell Non-Hodgkin Lymphoma","Refractory Acute Myeloid Leukemia","Refractory Anaplastic Large Cell Lymphoma","Refractory Angioimmunoblastic T-Cell Lymphoma","Refractory Mycosis Fungoides","Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified","Refractory Plasma Cell Myeloma","Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Refractory T-Cell Non-Hodgkin Lymphoma"],"enrollment":127,"completionDate":"2032-04-01"},{"nctId":"NCT07281417","phase":"PHASE2","title":"Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-11-24","conditions":["Sinonasal Squamous Cell Carcinoma","Stage III Sinonasal Cancer AJCC v8","Stage IVA Sinonasal Cancer AJCC v8","Stage IVB Sinonasal Cancer AJCC v8"],"enrollment":108,"completionDate":"2030-12-16"},{"nctId":"NCT06900595","phase":"PHASE2","title":"Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-02-22","conditions":["Locally Advanced Adrenal Cortical Carcinoma","Metastatic Adrenal Cortical Carcinoma","Recurrent Adrenal Cortical Carcinoma","Stage III Adrenal Cortical Carcinoma AJCC v8","Stage IV Adrenal Cortical Carcinoma AJCC v8","Unresectable Adrenal Cortical Carcinoma"],"enrollment":48,"completionDate":"2029-06-02"},{"nctId":"NCT07365839","phase":"PHASE1","title":"Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2026-07-01","conditions":["Hepatocellular Carcinoma"],"enrollment":20,"completionDate":"2035-02-28"},{"nctId":"NCT06651593","phase":"PHASE2","title":"Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-07-02","conditions":["Solid Tumors"],"enrollment":40,"completionDate":"2030-09-01"},{"nctId":"NCT05929664","phase":"PHASE2","title":"Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-07-05","conditions":["Locally Advanced Basal Cell Carcinoma","Basal Cell Carcinoma"],"enrollment":70,"completionDate":"2031-07-05"},{"nctId":"NCT06943664","phase":"PHASE2","title":"Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-05-15","conditions":["Lung Non-Small Cell Carcinoma","Metastatic Lung Non-Small Cell Carcinoma","Refractory Lung Non-Small Cell Carcinoma","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Stage IV Lung Cancer AJCC v8"],"enrollment":27,"completionDate":"2028-05-01"},{"nctId":"NCT04387084","phase":"PHASE1","title":"Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2020-08-12","conditions":["Advanced Malignant Skin Neoplasm","Metastatic Malignant Skin Neoplasm"],"enrollment":10,"completionDate":"2027-08-12"},{"nctId":"NCT06769698","phase":"PHASE2","title":"A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-31","conditions":["Head and Neck Squamous Cell Carcinoma (HNSCC)"],"enrollment":120,"completionDate":"2030-12-28"},{"nctId":"NCT07281768","phase":"PHASE2","title":"Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-04","conditions":["Colorectal Cancer"],"enrollment":66,"completionDate":"2030-04"},{"nctId":"NCT03491683","phase":"PHASE1,PHASE2","title":"INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inovio Pharmaceuticals","startDate":"2018-05-31","conditions":["Glioblastoma"],"enrollment":52,"completionDate":"2026-12-31"},{"nctId":"NCT06931717","phase":"PHASE3","title":"A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy","status":"RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2026-01-12","conditions":["Non-Small Cell Lung Cancer"],"enrollment":390,"completionDate":"2029-03"},{"nctId":"NCT05363319","phase":"","title":"An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-10-26","conditions":["Non-small Cell Lung Cancer"],"enrollment":500,"completionDate":"2028-10-30"},{"nctId":"NCT06205836","phase":"PHASE2","title":"Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2024-06-13","conditions":["Colorectal Cancer"],"enrollment":44,"completionDate":"2028-05"},{"nctId":"NCT06508463","phase":"PHASE1","title":"Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-01-05","conditions":["Peripheral T Cell Lymphoma","Relapsed Peripheral T-Cell Lymphoma","Peripheral T-Cell Lymphoma, Not Otherwise Specified","Anaplastic Large Cell Lymphoma","Mycosis Fungoides","Relapsed Anaplastic Large Cell Lymphoma","Relapsed Mycosis Fungoides"],"enrollment":21,"completionDate":"2032-04-01"},{"nctId":"NCT06162572","phase":"PHASE1,PHASE2","title":"Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Servier Bio-Innovation LLC","startDate":"2024-08-07","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"enrollment":100,"completionDate":"2027-07"},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":["Breast Neoplasms","Breast Cancer","Breast Tumors","Angiosarcoma","TNBC - Triple-Negative Breast Cancer","HER2-positive Breast Cancer","HER2-negative Breast Cancer","Hormone Receptor Positive Tumor","Hormone Receptor Negative Tumor","Early-stage Breast Cancer","Locally Advanced Breast Cancer"],"enrollment":5000,"completionDate":"2031-12"},{"nctId":"NCT07470489","phase":"PHASE2","title":"A Multi-Center Single-Arm Phase 2 Trial Of Zanzalintinib In Combination With Cemiplimab In BRAF Wild-Type Anaplastic Thyroid Cancer: The ZEPHYR Trial","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-09-30","conditions":["Anaplastic Thyroid Cancer"],"enrollment":12,"completionDate":"2032-09-01"},{"nctId":"NCT05401786","phase":"PHASE2","title":"Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2023-01-03","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":54,"completionDate":"2026-06"},{"nctId":"NCT06384807","phase":"PHASE1,PHASE2","title":"A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Biohaven Therapeutics Ltd.","startDate":"2024-04-22","conditions":["Solid Tumor"],"enrollment":500,"completionDate":"2028-02"},{"nctId":"NCT06981325","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-08-07","conditions":["Basal Cell Carcinoma (BCC)","First Line Treatment"],"enrollment":34,"completionDate":"2029-07"},{"nctId":"NCT06385262","phase":"PHASE2","title":"TOP 2301: Neoadjuvant Chemo for NSCLC","status":"SUSPENDED","sponsor":"Duke University","startDate":"2025-03-17","conditions":["Non Small Cell Lung Cancer"],"enrollment":126,"completionDate":"2029-10-30"},{"nctId":"NCT06171750","phase":"PHASE1","title":"Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Ankyra Therapeutics, Inc","startDate":"2024-01-19","conditions":["Advanced Solid Tumor","Cutaneous Tumor","Subcutaneous Tumor","Malignant Solid Tumor","Solid Tumor","Metastatic Solid Tumor","Metastasis to Soft Tissue","Non Small Cell Lung Cancer","Cutaneous Squamous Cell Carcinoma"],"enrollment":97,"completionDate":"2027-06"},{"nctId":"NCT06412198","phase":"PHASE1,PHASE2","title":"A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-08-28","conditions":["Metastatic Colorectal Cancer","KRAS G12C Mutations"],"enrollment":31,"completionDate":"2029-03-01"},{"nctId":"NCT06826768","phase":"PHASE1","title":"A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-07-09","conditions":["Prostate Cancer"],"enrollment":60,"completionDate":"2029-05-01"},{"nctId":"NCT07179315","phase":"PHASE2","title":"A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-12-01","conditions":["Head and Neck Cancer"],"enrollment":68,"completionDate":"2029-11-30"},{"nctId":"NCT06699602","phase":"PHASE2","title":"A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-02-11","conditions":["Renal Cell Carcinoma"],"enrollment":10,"completionDate":"2028-02"},{"nctId":"NCT07450183","phase":"PHASE2","title":"Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1","status":"NOT_YET_RECRUITING","sponsor":"Henry Ford Health System","startDate":"2026-06-01","conditions":["Lung Cancer (NSCLC)"],"enrollment":33,"completionDate":"2027-12-01"},{"nctId":"NCT04988074","phase":"PHASE2","title":"Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-12-13","conditions":["HPV-Related Squamous Cell Carcinoma"],"enrollment":32,"completionDate":"2027-12"},{"nctId":"NCT07223541","phase":"PHASE2","title":"Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2026-01-15","conditions":["Clear Cell Renal Cell Carcinoma"],"enrollment":72,"completionDate":"2031-08"},{"nctId":"NCT05125016","phase":"PHASE1,PHASE2","title":"A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-11-30","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":370,"completionDate":"2027-01-14"},{"nctId":"NCT07433673","phase":"PHASE2","title":"Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)","status":"RECRUITING","sponsor":"Columbia University","startDate":"2026-08","conditions":["Colon and Rectal Cancer"],"enrollment":20,"completionDate":"2029-01"},{"nctId":"NCT03565783","phase":"PHASE2","title":"Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-07-03","conditions":["Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck","Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck","Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8"],"enrollment":44,"completionDate":"2027-12-31"},{"nctId":"NCT06585410","phase":"PHASE3","title":"Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-01-02","conditions":["Cutaneous Squamous Cell Carcinoma (CSCC)"],"enrollment":369,"completionDate":"2030-05-03"},{"nctId":"NCT06918132","phase":"PHASE2","title":"Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-04-29","conditions":["Lung Non-Small Cell Carcinoma","Stage IB Lung Cancer AJCC v8","Stage II Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8"],"enrollment":60,"completionDate":"2027-04-29"},{"nctId":"NCT03088540","phase":"PHASE3","title":"Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","isPivotal":true,"startDate":"2017-05-29","conditions":["Carcinoma，Non-Small-Cell Lung","Lung Carcinomas, Non-Small-Cell","Non-small-cell Lung Carcinoma","Nonsmall Cell Lung Cancer"],"enrollment":712,"completionDate":"2025-04-18"},{"nctId":"NCT06219317","phase":"PHASE2","title":"Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-01-14","conditions":["NSCLC Stage IV"],"enrollment":136,"completionDate":"2030-01"},{"nctId":"NCT07188896","phase":"PHASE2","title":"A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)","status":"RECRUITING","sponsor":"Brian Rini","startDate":"2026-03","conditions":["Advanced Renal Cell Carcinoma (aRCC)","Metastatic Renal Cell Carcinoma ( mRCC)","Clear Cell Renal Cell Carcinoma (ccRCC)"],"enrollment":120,"completionDate":"2030-11"},{"nctId":"NCT06855212","phase":"PHASE2","title":"Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2025-02-26","conditions":["Head and Neck Squamous Cell Carcinoma"],"enrollment":21,"completionDate":"2028-03"},{"nctId":"NCT06246916","phase":"PHASE3","title":"A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-09-09","conditions":["Melanoma"],"enrollment":560,"completionDate":"2033-07-10"},{"nctId":"NCT07418931","phase":"PHASE2","title":"A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2026-05","conditions":["Advanced Squamous Non-Small Cell Lung Cancer"],"enrollment":108,"completionDate":"2030-11"},{"nctId":"NCT06787612","phase":"PHASE2","title":"Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-05-28","conditions":["Ovarian Cancer"],"enrollment":220,"completionDate":"2028-12-07"},{"nctId":"NCT07414992","phase":"PHASE2","title":"A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-03","conditions":["Bladder Urothelial Carcinoma"],"enrollment":44,"completionDate":"2028-03"},{"nctId":"NCT05882734","phase":"PHASE1,PHASE2","title":"Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)","status":"ACTIVE_NOT_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2023-09-13","conditions":["Non-Small Cell Lung Cancer"],"enrollment":61,"completionDate":"2026-03-30"},{"nctId":"NCT06731270","phase":"PHASE2","title":"Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-04-09","conditions":["Advanced Lung Non-Small Cell Carcinoma","Metastatic Lung Non-Small Cell Carcinoma","Stage III Lung Cancer AJCC v8","Stage IV Lung Cancer AJCC v8"],"enrollment":20,"completionDate":"2028-01-01"},{"nctId":"NCT06465329","phase":"PHASE2","title":"A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-11-18","conditions":["Non-Small Cell Lung Cancer"],"enrollment":120,"completionDate":"2030-05-02"},{"nctId":"NCT03233139","phase":"PHASE1","title":"Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-06-21","conditions":["Advanced Malignancies"],"enrollment":146,"completionDate":"2027-09-30"},{"nctId":"NCT06449313","phase":"PHASE2","title":"Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement","status":"RECRUITING","sponsor":"Georgetown University","startDate":"2026-04","conditions":["Non-small Cell Lung Cancer Stage III"],"enrollment":21,"completionDate":"2032-09"},{"nctId":"NCT07404332","phase":"PHASE1","title":"5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors","status":"NOT_YET_RECRUITING","sponsor":"Mohammed Milhem","startDate":"2026-02-28","conditions":["Solid Tumor","Locally Advanced Solid Tumor","Metastatic Tumor"],"enrollment":35,"completionDate":"2031-02-28"},{"nctId":"NCT06656598","phase":"PHASE2","title":"Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2025-11-07","conditions":["Stage III NSCLC"],"enrollment":152,"completionDate":"2032-01"},{"nctId":"NCT07234058","phase":"PHASE2","title":"Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma","status":"NOT_YET_RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2026-02","conditions":["Pleural Mesotheliomas"],"enrollment":126,"completionDate":"2029-09"},{"nctId":"NCT06190951","phase":"PHASE2","title":"A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-09-18","conditions":["Melanoma"],"enrollment":151,"completionDate":"2030-12-09"},{"nctId":"NCT04862650","phase":"PHASE2","title":"Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"Marcelo Bonomi","startDate":"2021-11-30","conditions":["Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Metastatic Head and Neck Squamous Cell Carcinoma","Metastatic Hypopharyngeal Squamous Cell Carcinoma","Metastatic Laryngeal Squamous Cell Carcinoma","Metastatic Oral Cavity Squamous Cell Carcinoma","Metastatic Oropharyngeal Squamous Cell Carcinoma","Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Recurrent Head and Neck Squamous Cell Carcinoma","Recurrent Hypopharyngeal Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Oral Cavity Squamous Cell Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma","Squamous Cell Carcinoma of Unknown Primary","Stage IV Hypopharyngeal Carcinoma AJCC v8","Stage IV Laryngeal Cancer AJCC v8","Stage IV Lip and Oral Cavity Cancer AJCC v8","Stage IVA Hypopharyngeal Carcinoma AJCC v8","Stage IVA Laryngeal Cancer AJCC v8","Stage IVA Lip and Oral Cavity Cancer AJCC v8","Stage IVB Hypopharyngeal Carcinoma AJCC v8","Stage IVB Laryngeal Cancer AJCC v8","Stage IVB Lip and Oral Cavity Cancer AJCC v8","Stage IVC Hypopharyngeal Carcinoma AJCC v8","Stage IVC Laryngeal Cancer AJCC v8","Stage IVC Lip and Oral Cavity Cancer AJCC v8"],"enrollment":46,"completionDate":"2026-12-31"},{"nctId":"NCT07360743","phase":"PHASE2","title":"Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-04","conditions":["Non Small Cell Lung Cancer (Squamous or Non Squamous)"],"enrollment":275,"completionDate":"2032-04"},{"nctId":"NCT05358938","phase":"EARLY_PHASE1","title":"Exercise to Boost Response to Checkpoint Blockade Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-06-21","conditions":["Cutaneous Melanoma","Cutaneous Squamous Cell Carcinoma","Merkel Cell Carcinoma"],"enrollment":22,"completionDate":"2026-08"},{"nctId":"NCT07224022","phase":"PHASE2","title":"Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"John Strickler, M.D.","startDate":"2026-02","conditions":["Colon Cancer"],"enrollment":24,"completionDate":"2029-07"},{"nctId":"NCT04913220","phase":"PHASE1,PHASE2","title":"A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)","status":"TERMINATED","sponsor":"Sanofi","startDate":"2021-07-15","conditions":["Malignant Melanoma","Squamous Cell Carcinoma of Skin"],"enrollment":46,"completionDate":"2025-02-18"},{"nctId":"NCT07387198","phase":"PHASE2","title":"Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab","status":"NOT_YET_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2026-02-28","conditions":["Merkel Cell Carcinoma, Stage I","Merkel Cell Carcinoma, Stage II","Neoadjuvant Immunotherapy"],"enrollment":135,"completionDate":"2031-07-31"},{"nctId":"NCT06469281","phase":"PHASE1","title":"A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-08-06","conditions":["Epithelial Ovarian Cancer","Primary Peritoneal Carcinoma","Fallopian Tube Cancer"],"enrollment":90,"completionDate":"2030-05-27"},{"nctId":"NCT05139706","phase":"","title":"Montreal Immune-Related Adverse Events (MIRAE) Study","status":"RECRUITING","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2020-01-21","conditions":["Cancer","Immune System Disorder","Inflammatory Reaction","Autoimmune Diseases"],"enrollment":1000,"completionDate":"2030-01"},{"nctId":"NCT04626635","phase":"PHASE1,PHASE2","title":"A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-12-21","conditions":["Advanced Solid Tumors"],"enrollment":933,"completionDate":"2027-04-07"},{"nctId":"NCT02651662","phase":"PHASE1","title":"A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-01-11","conditions":["Relapsed/Refractory Aggressive B-Cell Lymphoma"],"enrollment":105,"completionDate":"2026-05-31"},{"nctId":"NCT06860815","phase":"PHASE2","title":"Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-04-01","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Carcinoma","Metastatic Carcinoma in the Liver"],"enrollment":11,"completionDate":"2027-01-30"},{"nctId":"NCT04989946","phase":"PHASE1,PHASE2","title":"Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-12-16","conditions":["Prostate Cancer"],"enrollment":60,"completionDate":"2028-12"},{"nctId":"NCT06923761","phase":"PHASE1,PHASE2","title":"EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)","status":"RECRUITING","sponsor":"Grey Wolf Therapeutics","startDate":"2023-05-21","conditions":["Advanced Solid Malignancy"],"enrollment":300,"completionDate":"2028-04-30"},{"nctId":"NCT05694871","phase":"PHASE2","title":"Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-06-07","conditions":["Advanced Dedifferentiated Liposarcoma","Locally Advanced Dedifferentiated Liposarcoma","Metastatic Dedifferentiated Liposarcoma","Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","Unresectable Dedifferentiated Liposarcoma"],"enrollment":77,"completionDate":"2027-05-31"},{"nctId":"NCT06616584","phase":"PHASE2,PHASE3","title":"Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2025-05-22","conditions":["Recurrent Lung Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8"],"enrollment":378,"completionDate":"2028-12-31"},{"nctId":"NCT05553834","phase":"PHASE2","title":"PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung","status":"ACTIVE_NOT_RECRUITING","sponsor":"Duke University","startDate":"2023-05-16","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"enrollment":60,"completionDate":"2026-03-01"},{"nctId":"NCT05800015","phase":"PHASE2,PHASE3","title":"A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-08-08","conditions":["Non-small Cell Lung Cancer"],"enrollment":950,"completionDate":"2031-12-23"},{"nctId":"NCT05785767","phase":"PHASE2,PHASE3","title":"A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-06-30","conditions":["Advanced Non-Small Cell Lung Cancer"],"enrollment":850,"completionDate":"2032-02-05"},{"nctId":"NCT05137054","phase":"PHASE1","title":"A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-08-17","conditions":["Multiple Myeloma"],"enrollment":317,"completionDate":"2034-09-26"},{"nctId":"NCT03889912","phase":"PHASE1","title":"Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2019-04-11","conditions":["Cutaneous Squamous Cell Carcinoma","Basal Cell Carcinoma"],"enrollment":97,"completionDate":"2025-12-10"},{"nctId":"NCT07346196","phase":"PHASE2","title":"A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2027-02-07","conditions":["Squamous Cell Carcinoma"],"enrollment":90,"completionDate":"2031-08-22"},{"nctId":"NCT05208944","phase":"PHASE2","title":"THIO Sequenced With Cemiplimab in Advanced NSCLC","status":"RECRUITING","sponsor":"Maia Biotechnology","startDate":"2022-06-08","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":227,"completionDate":"2027-12-31"},{"nctId":"NCT06302426","phase":"PHASE1","title":"Trial of INI-4001 in Patients With Advanced Solid Tumours","status":"RECRUITING","sponsor":"Inimmune Corporation","startDate":"2024-07-01","conditions":["Advanced Solid Tumor"],"enrollment":50,"completionDate":"2027-03-30"},{"nctId":"NCT06790602","phase":"PHASE2","title":"Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-01","conditions":["Pancreatic Ductal Adenocarcinoma (mPDAC)"],"enrollment":43,"completionDate":"2029-12"},{"nctId":"NCT06848088","phase":"PHASE2","title":"A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment","status":"ENROLLING_BY_INVITATION","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-04-14","conditions":["Melanoma"],"enrollment":48,"completionDate":"2029-10-10"},{"nctId":"NCT06908304","phase":"PHASE3","title":"A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC","status":"RECRUITING","sponsor":"Maia Biotechnology","startDate":"2025-12-08","conditions":["Carcinoma, Non-Small -Cell Lung"],"enrollment":300,"completionDate":"2027-12-31"},{"nctId":"NCT06161441","phase":"PHASE2","title":"A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-07-16","conditions":["Resectable Non-small Cell Lung Cancer"],"enrollment":195,"completionDate":"2029-11-04"},{"nctId":"NCT06444880","phase":"PHASE2","title":"Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-10-09","conditions":["SMARCB1-Deficient Malignancies"],"enrollment":40,"completionDate":"2028-07-31"},{"nctId":"NCT04526899","phase":"PHASE2","title":"A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2021-05-19","conditions":["Melanoma Stage III","Melanoma Stage IV","Unresectable Melanoma"],"enrollment":184,"completionDate":"2025-11-24"},{"nctId":"NCT06022029","phase":"PHASE1","title":"A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.","status":"RECRUITING","sponsor":"OncoNano Medicine, Inc.","startDate":"2023-10-13","conditions":["Triple Negative Breast Cancer","Diffuse Large B Cell Lymphoma","Follicular Lymphoma","Lymphoma, Non-Hodgkin","Mantle Cell Lymphoma","Bladder Cancer","Uveal Melanoma, Recurrent","Cervix Cancer","Carcinoma in Situ","Head and Neck Squamous Cell Carcinoma","Skin Cancer","Metastatic Cancer","Tumor, Solid","Tumor Recurrence"],"enrollment":168,"completionDate":"2026-08-29"},{"nctId":"NCT04154943","phase":"PHASE2","title":"Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-03-10","conditions":["Cutaneous Squamous Cell Carcinoma"],"enrollment":79,"completionDate":"2025-11-19"},{"nctId":"NCT05352672","phase":"PHASE3","title":"Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-07-14","conditions":["Melanoma"],"enrollment":1546,"completionDate":"2031-09-16"},{"nctId":"NCT06413680","phase":"PHASE1,PHASE2","title":"A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-09-23","conditions":["Melanoma","Clear-Cell Renal-Cell Carcinoma (ccRCC)","Advanced Solid Tumors"],"enrollment":240,"completionDate":"2030-02-03"},{"nctId":"NCT04157985","phase":"PHASE3","title":"Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dan Zandberg","startDate":"2019-11-15","conditions":["Advanced Solid Tumors","NSCLC","Bladder Cancer","HNSCC","Renal Cancer","Melanoma","Anal Cancer","Colorectal Cancer","Cholangiocarcinoma","Gastric Cancer","Hepatocellular Carcinoma","Merkel Cell Carcinoma","Cervical Cancer"],"enrollment":161,"completionDate":"2025-11-07"},{"nctId":"NCT07274384","phase":"PHASE2","title":"Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial","status":"NOT_YET_RECRUITING","sponsor":"Università Vita-Salute San Raffaele","startDate":"2026-01-01","conditions":["NSCLC (Non-small Cell Lung Cancer)","Hyperprogression"],"enrollment":74,"completionDate":"2030-06-01"},{"nctId":"NCT05317858","phase":"PHASE3","title":"Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets","status":"RECRUITING","sponsor":"InSightec","startDate":"2022-08-12","conditions":["Brain Tumor","Non Small Cell Lung Cancer"],"enrollment":30,"completionDate":"2027-12-01"},{"nctId":"NCT07224971","phase":"PHASE2","title":"Impact of Circadian Rhythm on Immunotherapy","status":"RECRUITING","sponsor":"Liza Villaruz, MD","startDate":"2025-12-02","conditions":["Advanced/Metastatic NSCLC"],"enrollment":350,"completionDate":"2030-05-01"},{"nctId":"NCT04916002","phase":"PHASE2","title":"A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-11-30","conditions":["Merkel Cell Carcinoma","Cutaneous Squamous Cell Carcinoma","Basal Cell Carcinoma","Triple Negative Breast Cancer","Non-Small Cell Lung Cancer","Oropharynx Squamous Cell Carcinoma"],"enrollment":77,"completionDate":"2024-10-31"},{"nctId":"NCT04975152","phase":"PHASE1","title":"Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-10-22","conditions":["Merkel Cell Carcinoma","Cutaneous Squamous Cell Carcinoma"],"enrollment":36,"completionDate":"2028-03"}],"_emaApprovals":[{"date":"2019-06-28","status":"Authorised","company":"REGENERON IRELAND U.C."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT02383212","NCT02760498","NCT03132636","NCT03088540"],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"LIBTAYO"}]},"crossReferences":{"MMSL":"292661","NDDF":"017771","UNII":"6QVL057INT","VANDF":"4037905","INN_ID":"10691","RXNORM":"2058825","UMLSCUI":"C4724806","chemblId":"CHEMBL4297723","ChEMBL_ID":"CHEMBL4297723","KEGG_DRUG":"D11108","DRUGBANK_ID":"DB14707","SNOMEDCT_US":"781555007","IUPHAR_LIGAND_ID":"10090","MESH_SUPPLEMENTAL_RECORD_UI":"C000627974"},"formularyStatus":[],"originalProduct":{"form":"INJECTION","route":"INTRAVENOUS","company":"Regeneron Pharmaceuticals, Inc.","brandName":"LIBTAYO","isOriginal":true,"marketingStatus":"BLA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2018-","companyName":"Regeneron","relationship":"Original Developer"},{"period":"2019","companyName":"Regeneron Ireland U.C.","relationship":"EMA Licensee"},{"period":"2022","companyName":"Sanofi K.K.","relationship":"PMDA Licensee"}],"publicationCount":716,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-08 13:58:44.31108+00","atcClassification":{"source":"DrugCentral","atcCode":"L01FF06","allCodes":["L01FF06"]},"biosimilarFilings":[],"originalDeveloper":"Regeneron Pharmaceuticals ","recentPublications":[{"date":"2026 Mar 12","pmid":"41899521","title":"Association Between Patient-Reported Outcomes and Overall Survival in Patients with Advanced NSCLC Treated with First-Line Cemiplimab-Based Therapy.","journal":"Cancers"},{"date":"2026 Apr","pmid":"41869512","title":"First-Line Cemiplimab for Locally Advanced NSCLC: Updated Subgroup Analyses From the EMPOWER-Lung 1 and EMPOWER-Lung 3 Trials.","journal":"JTO clinical and research reports"},{"date":"2026","pmid":"41868132","title":"Effectiveness and safety of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.","journal":"Frontiers in pharmacology"},{"date":"2026 Dec","pmid":"41861397","title":"Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non-small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparison.","journal":"Journal of medical economics"},{"date":"2026 Mar 19","pmid":"41855018","title":"ASO Visual Abstract: The Role of Cemiplimab in Treating Locally Advanced Cutaneous SCC-A UK Single-Centre Experience and the Implications for Surgical Management.","journal":"Annals of surgical oncology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Regeneron Pharmaceuticals ","companyId":"regeneron","modality":"Monoclonal antibody","firstApprovalDate":"2018","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-04-28T00:00:00.000Z","mah":"REGENERON PHARMACEUTICALS","brand_name_local":null,"application_number":"BLA761097"},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":2},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T00:46:30.569644+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}